D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
| Title | Journal |
|---|---|
| Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. | Chemical research in toxicology 20170515 |
| Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. | PloS one 20170101 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands. | Bioorganic & medicinal chemistry letters 20140601 |
| High-affinity recognition of HIV-1 frameshift-stimulating RNA alters frameshifting in vitro and interferes with HIV-1 infectivity. | Journal of medicinal chemistry 20140213 |
| Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. | PLoS pathogens 20140201 |
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
| Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. | Chemistry & biology 20130919 |
| Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20130912 |
| Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease. | Bioorganic & medicinal chemistry 20130901 |
| Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors. | Antiviral research 20130401 |
| Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. | Retrovirology 20130101 |
| Effect of HIV protease inhibitors on New World Leishmania. | Parasitology international 20121201 |
| Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors. | Proteins 20121201 |
| New furanones from the plant endophytic fungus Pestalotiopsis besseyi. | Molecules (Basel, Switzerland) 20121127 |
| Role of FAP48 in HIV-associated lipodystrophy. | Journal of cellular biochemistry 20121101 |
| Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. | Antimicrobial agents and chemotherapy 20121101 |
| Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. | AIDS research and human retroviruses 20121001 |
| Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. | AIDS research and human retroviruses 20120901 |
| Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. | Scandinavian journal of infectious diseases 20120901 |
| Prevalence of nephrolithiasis in human immunodeficiency virus infected patients on the highly active antiretroviral therapy. | Journal of endourology 20120801 |
| Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS. | Journal of chromatographic science 20120801 |
| Regression analysis based on conditional likelihood approach under semi-competing risks data. | Lifetime data analysis 20120701 |
| Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. | Antimicrobial agents and chemotherapy 20120701 |
| Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans. | Canadian journal of microbiology 20120701 |
| The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. | Pharmacological reviews 20120701 |
| Herb-drug interactions and mechanistic and clinical considerations. | Current drug metabolism 20120601 |
| Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. | AIDS (London, England) 20120601 |
| HIV therapies and the kidney: some good, some not so good? | Current HIV/AIDS reports 20120601 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. | AIDS (London, England) 20120515 |
| Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. | European journal of clinical pharmacology 20120501 |
| Achieving a cure for HIV infection: do we have reasons to be optimistic? | The Journal of antimicrobial chemotherapy 20120501 |
| HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G. | The Journal of antimicrobial chemotherapy 20120501 |
| Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats. | The Journal of steroid biochemistry and molecular biology 20120501 |
| Quality of life of people with HIV/AIDS receiving antiretroviral therapy in Cuba: a cross-sectional study of the national population. | American journal of public health 20120501 |
| Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. | The Cochrane database of systematic reviews 20120418 |
| Validating the vitality strategy for fighting drug resistance. | Proteins 20120401 |
| Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401 |
| N-Cyclo-pentyl-N-(3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide. | Acta crystallographica. Section E, Structure reports online 20120401 |
| Nanotechnology and the treatment of HIV infection. | Viruses 20120401 |
| Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors. | Journal of medicinal chemistry 20120322 |
| Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models. | Biometrics 20120301 |
| Exploring the complexity of the HIV-1 fitness landscape. | PLoS genetics 20120301 |
| Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa. | International journal of STD & AIDS 20120301 |
| Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120215 |
| Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. | Molecular pharmacology 20120201 |
| Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). | Anesthesiology 20120201 |
| Novel approaches to inhibit HIV entry. | Viruses 20120201 |
| Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. | AIDS (London, England) 20120128 |
| Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20120101 |
| Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. | International journal of vascular medicine 20120101 |
| The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. | Journal of neurochemistry 20120101 |
| Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. | PloS one 20120101 |
| Intraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatment. | PloS one 20120101 |
| HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. | Advances in hematology 20120101 |
| Efflux protein expression in human stem cell-derived retinal pigment epithelial cells. | PloS one 20120101 |
| Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. | Journal of biomedical science 20120101 |
| Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments. | AIDS research and therapy 20120101 |
| Bilirubin, renal hemodynamics, and blood pressure. | Frontiers in pharmacology 20120101 |
| Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. | PloS one 20120101 |
| Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs. | In vivo (Athens, Greece) 20120101 |
| Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. | PloS one 20120101 |
| Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. | PloS one 20120101 |
| Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex. | PloS one 20120101 |
| Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. | Retrovirology 20120101 |
| Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness. | AIDS research and therapy 20120101 |
| HIV RNA suppression and immune restoration: can we do better? | Clinical & developmental immunology 20120101 |
| HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. | PloS one 20120101 |
| HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. | International journal of hepatology 20120101 |
| Occupational exposure to human immunodeficiency virus in health care providers: a retrospective analysis. | Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine 20120101 |
| Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. | AIDS research and treatment 20120101 |
| Effect of a New Prokinetic Agent DA-9701 Formulated with Corydalis Tuber and Pharbitidis Semen on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| An overview of the evidence and mechanisms of herb-drug interactions. | Frontiers in pharmacology 20120101 |
| Sudden death of cardiac origin and psychotropic drugs. | Frontiers in pharmacology 20120101 |
| Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. | PloS one 20120101 |
| Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. | PloS one 20120101 |
| Expression of Tight Junction and Drug Efflux Transporter Proteins in an in vitro Model of Human Blood-Brain Barrier. | Frontiers in psychiatry 20120101 |
| A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011. | The Pan African medical journal 20120101 |
| Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008. | AIDS research and treatment 20120101 |
| Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs. | PloS one 20120101 |
| Measuring the efficacy of antiretroviral therapy. | International journal of trichology 20120101 |
| Ethionamide-induced gynecomastia. | Journal of pharmacology & pharmacotherapeutics 20120101 |
| Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. | International journal of nanomedicine 20120101 |
| The molecular mechanism of action of the CR6261-Azichromycin combination found through computational analysis. | PloS one 20120101 |
| Malaria and hiv in adults: when the parasite runs into the virus. | Mediterranean journal of hematology and infectious diseases 20120101 |
| Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. | PloS one 20120101 |
| Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. | Nanotoxicology 20111201 |
| Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. | Parasitology research 20111201 |
| Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. | Alcoholism, clinical and experimental research 20111201 |
| Inhibition of the protein tyrosine phosphatase SHP-1 increases glucose uptake in skeletal muscle cells by augmenting insulin receptor signaling and GLUT4 expression. | Endocrinology 20111201 |
| Pulmonary arterial hypertension: an update. | Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks. | Gut and liver 20111201 |
| Diagnosis & treatment of tuberculosis in HIV co-infected patients. | The Indian journal of medical research 20111201 |
| Human immunodeficiency virus & cardiovascular risk. | The Indian journal of medical research 20111201 |
| How much do antiretroviral drugs penetrate into the central nervous system? | Journal of medicine and life 20111114 |
| Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. | The Journal of pharmacology and experimental therapeutics 20111101 |
| Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. | PLoS pathogens 20111101 |
| Evaluation of metabolism-mediated herb-drug interactions. | Archives of pharmacal research 20111101 |
| HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. | The Lancet. Infectious diseases 20111001 |
| Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors. | Journal of pharmaceutical sciences 20110901 |
| Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): biological assay. | The journal of obstetrics and gynaecology research 20110901 |
| Brain delivery of transferrin coupled indinavir submicron lipid emulsions--pharmacokinetics and tissue distribution. | Colloids and surfaces. B, Biointerfaces 20110901 |
| Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
| The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. | Parasitology 20110901 |
| Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. | PLoS pathogens 20110901 |
| Why don't CD8+ T cells reduce the lifespan of SIV-infected cells in vivo? | PLoS computational biology 20110901 |
| Pairwise additivity of energy components in protein-ligand binding: the HIV II protease-Indinavir case. | The Journal of chemical physics 20110828 |
| Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. | Journal of medicinal chemistry 20110825 |
| Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. | AIDS (London, England) 20110824 |
| Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110815 |
| Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. | British journal of cancer 20110809 |
| Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801 |
| UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801 |
| Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa. | Journal of health, population, and nutrition 20110801 |
| Risk factors of chronic kidney disease in HIV-infected patients. | Clinical journal of the American Society of Nephrology : CJASN 20110701 |
| Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands. | Bioorganic & medicinal chemistry letters 20110615 |
| Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. | International urology and nephrology 20110601 |
| The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. | Antimicrobial agents and chemotherapy 20110601 |
| Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. | Journal of urban health : bulletin of the New York Academy of Medicine 20110601 |
| Fluorescence spectroscopy as tool for bone development monitoring in newborn rats. | Journal of fluorescence 20110501 |
| Surface structured liposomes for site specific delivery of an antiviral agent-indinavir. | Journal of drug targeting 20110501 |
| [Characteristics of antiretroviral drugs]. | Enfermedades infecciosas y microbiologia clinica 20110501 |
| Human immunodeficiency virus therapeutics and pharmacogenomics. | Indian journal of human genetics 20110501 |
| Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. | Journal of acquired immune deficiency syndromes (1999) 20110501 |
| Proper laboratory notebook practices: protecting your intellectual property. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401 |
| Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. | Free radical biology & medicine 20110401 |
| Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. | Clinical pharmacokinetics 20110401 |
| The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. | Therapeutic drug monitoring 20110401 |
| Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. | PLoS computational biology 20110401 |
| Clinical management of HIV drug resistance. | Viruses 20110401 |
| A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. | Journal of pharmaceutical and biomedical analysis 20110325 |
| Brain specific delivery of pegylated indinavir submicron lipid emulsions. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110318 |
| Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. | Journal of controlled release : official journal of the Controlled Release Society 20110310 |
| Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. | Biometrics 20110301 |
| In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete. | Toxicology in vitro : an international journal published in association with BIBRA 20110301 |
| Crystalluria: prevalence, different types of crystals and the role of infrared spectroscopy. | Clinical chemistry and laboratory medicine 20110301 |
| The search for host genetic factors of HIV/AIDS pathogenesis in the post-genome era: progress to date and new avenues for discovery. | Current HIV/AIDS reports 20110301 |
| Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery. | AAPS PharmSciTech 20110301 |
| The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors. | Memorias do Instituto Oswaldo Cruz 20110301 |
| Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. | Sexually transmitted infections 20110201 |
| Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir. | Therapeutic drug monitoring 20110201 |
| Indinavir resistance evolution: a comment. | Virologica Sinica 20110201 |
| From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients. | Journal of clinical medicine research 20110201 |
| Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. | AIDS (London, England) 20110128 |
| Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. | Journal of medicinal chemistry 20110127 |
| Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. | International journal of cancer 20110101 |
| Determination of the antiretroviral drug nevirapine in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode. | Combinatorial chemistry & high throughput screening 20110101 |
| Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20110101 |
| The anti-tumor effects of human immunodeficiency virus protease inhibitors: ready for real time? | International journal of cancer 20110101 |
| Targeted Therapy of Ewing's Sarcoma. | Sarcoma 20110101 |
| Renal disease associated with antiretroviral therapy in the treatment of HIV. | Nephron. Clinical practice 20110101 |
| Understanding diabetes in patients with HIV/AIDS. | Diabetology & metabolic syndrome 20110101 |
| Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. | BMC medicine 20110101 |
| Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101 |
| Human immunodeficiency virus type 2 in two Saudi families. | Annals of Saudi medicine 20110101 |
| Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. | Journal of medical case reports 20110101 |
| Penicillium marneffei Infection in AIDS. | Pathology research international 20110101 |
| Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. | AIDS research and therapy 20110101 |
| Timely HAART initiation may pave the way for a better viral control. | BMC infectious diseases 20110101 |
| Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. | PloS one 20110101 |
| Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. | PloS one 20110101 |
| Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. | PloS one 20110101 |
| Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies. | PloS one 20110101 |
| 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice. | PloS one 20110101 |
| Sex differences in drug disposition. | Journal of biomedicine & biotechnology 20110101 |
| Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease. | Retrovirology 20110101 |
| Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. | Radiation oncology (London, England) 20110101 |
| High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. | Journal of the International AIDS Society 20110101 |
| Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis. | The Indian journal of tuberculosis 20110101 |
| Machine learning on normalized protein sequences. | BMC research notes 20110101 |
| Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. | PloS one 20110101 |
| Activation of latent HIV using drug-loaded nanoparticles. | PloS one 20110101 |
| The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. | European journal of medical research 20110101 |
| A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. | BMC bioinformatics 20110101 |
| Monitoring Antiretroviral Therapy in HIV-Infected Children in Resource-Limited Countries: A Tale of Two Epidemics. | AIDS research and treatment 20110101 |
| Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. | AIDS research and treatment 20110101 |
| Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. | AIDS research and treatment 20110101 |
| Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. | Breast cancer : basic and clinical research 20110101 |
| Multilevel Parallelization of AutoDock 4.2. | Journal of cheminformatics 20110101 |
| Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. | Malaria journal 20110101 |
| Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. | PloS one 20110101 |
| Safety and tolerability of antiretrovirals during pregnancy. | Infectious diseases in obstetrics and gynecology 20110101 |
| Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. | PloS one 20110101 |
| HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. | The open medicinal chemistry journal 20110101 |
| Contraception in HIV-positive female adolescents. | AIDS research and therapy 20110101 |
| HIV and HAART-Associated Dyslipidemia. | The open cardiovascular medicine journal 20110101 |
| Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. | Molecular brain 20110101 |
| Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. | PloS one 20110101 |
| Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. | PloS one 20110101 |
| Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. | PloS one 20110101 |
| Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana. | AIDS research and treatment 20110101 |
| Does HAART efficacy translate to effectiveness? Evidence for a trial effect. | PloS one 20110101 |
| Synthesis and Biological Evaluation of New 3-Phenyl-1-[(4-arylpiperazin-1-yl)alkyl]-piperidine-2,6-diones. | Scientia pharmaceutica 20110101 |
| Clinical therapeutics in pregnancy. | Journal of biomedicine & biotechnology 20110101 |
| Antiamnesic activity of an ayurvedic formulation chyawanprash in mice. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Genital lesions: An indication for changing ART regimen. | Indian journal of sexually transmitted diseases and AIDS 20110101 |
| Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. | PloS one 20110101 |
| Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. | PloS one 20110101 |
| Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. | Journal of nanobiotechnology 20110101 |
| [Evidence-based therapeutic drug monitoring for indinavir]. | Therapie 20110101 |
| Development of a classification scheme for disease-related enzyme information. | BMC bioinformatics 20110101 |
| The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. | Retrovirology 20110101 |
| Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. | Patient preference and adherence 20110101 |
| Nephrotoxicity of HAART. | AIDS research and treatment 20110101 |
| HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. | Retrovirology 20110101 |
| Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study. | BMC nephrology 20110101 |
| HIV-Associated Venous Thromboembolism. | Mediterranean journal of hematology and infectious diseases 20110101 |
| Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. | PloS one 20110101 |
| Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. | BMC public health 20110101 |
| Clinical herbal interactions with conventional drugs: from molecules to maladies. | Current medicinal chemistry 20110101 |
| Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. | PloS one 20110101 |
| Increased prevalence of albuminuria in HIV-infected adults with diabetes. | PloS one 20110101 |
| Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. | PloS one 20110101 |
| Quality of online pharmacies and websites selling prescription drugs: a systematic review. | Journal of medical Internet research 20110101 |
| Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. | Journal of pharmacy & bioallied sciences 20110101 |
| HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. | PloS one 20110101 |
| Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions. | Retrovirology 20110101 |
| Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. | Journal of thyroid research 20110101 |
| Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. | Indian journal of sexually transmitted diseases and AIDS 20110101 |
| Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature. | Indian journal of urology : IJU : journal of the Urological Society of India 20110101 |
| Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. | PloS one 20110101 |
| Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. | Indian journal of endocrinology and metabolism 20110101 |
| Human immunodeficiency virus endocrinopathy. | Indian journal of endocrinology and metabolism 20110101 |
| Choosing a gliptin. | Indian journal of endocrinology and metabolism 20110101 |
| Drugs for malaria: something old, something new, something borrowed. | F1000 biology reports 20110101 |
| It is time to consider third-line options in antiretroviral-experienced paediatric patients? | Journal of the International AIDS Society 20110101 |
| Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs. | Doklady. Biochemistry and biophysics 20110101 |
| Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Wild-type Drosophila melanogaster as a model host to analyze nitrogen source dependent virulence of Candida albicans. | PloS one 20110101 |
| AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. | BMC research notes 20110101 |
| Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. | PloS one 20110101 |
| A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function. | PloS one 20110101 |
| Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. | Retrovirology 20110101 |
| Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. | Cardiovascular diabetology 20110101 |
| Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. | Antiviral therapy 20110101 |
| Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. | BMC infectious diseases 20110101 |
| Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. | Journal of advanced pharmaceutical technology & research 20110101 |
| A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. | BMC bioinformatics 20110101 |
| Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. | BMC pulmonary medicine 20110101 |
| Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. | PloS one 20110101 |
| Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. | PloS one 20110101 |
| Nanomedicine as an emerging approach against intracellular pathogens. | International journal of nanomedicine 20110101 |
| Critical appraisal of ticagrelor in the management of acute coronary syndrome. | Therapeutics and clinical risk management 20110101 |
| Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. | International journal of nanomedicine 20110101 |
| Osteopenia and osteoporosis in people living with HIV: multiprofessional approach. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Lipodystrophy in HIV patients: its challenges and management approaches. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma. | Indian journal of pharmaceutical sciences 20110101 |
| Patient counseling about herbal-drug interactions. | African journal of traditional, complementary, and alternative medicines : AJTCAM 20110101 |
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | Toxicological sciences : an official journal of the Society of Toxicology 20101201 |
| NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. | Endocrinology 20101201 |
| CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy. | Cancer science 20101201 |
| Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. | Analytical and bioanalytical chemistry 20101201 |
| Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. | International journal of epidemiology 20101201 |
| Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. | Viruses 20101201 |
| HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes. | The Indian journal of medical research 20101201 |
| Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. | The Indian journal of medical research 20101201 |
| Spinal cord toxoplasmosis as an unusual presentation of AIDS: case report and review of the literature. | International journal of emergency medicine 20101201 |
| HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces. | Mycoses 20101101 |
| Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. | Cancer chemotherapy and pharmacology 20101101 |
| Molecular Basis for Drug Resistance in HIV-1 Protease. | Viruses 20101101 |
| Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies. | Statistics in medicine 20101015 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. | European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 20101001 |
| Requirement for distinct vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. | Diabetologia 20101001 |
| Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. | Toxicological sciences : an official journal of the Society of Toxicology 20101001 |
| Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 20101001 |
| Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. | Diabetes care 20101001 |
| Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. | American journal of physiology. Regulatory, integrative and comparative physiology 20101001 |
| Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification. | Virologica Sinica 20101001 |
| Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. | AIDS (London, England) 20100910 |
| Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. | European journal of medicinal chemistry 20100901 |
| Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. | Analytical and bioanalytical chemistry 20100901 |
| Antiepileptic drug interactions - principles and clinical implications. | Current neuropharmacology 20100901 |
| Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. | Nanomedicine : nanotechnology, biology, and medicine 20100801 |
| Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. | Antimicrobial agents and chemotherapy 20100801 |
| A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. | Clinical chemistry and laboratory medicine 20100801 |
| Methadone, buprenorphine, and street drug interactions with antiretroviral medications. | Current HIV/AIDS reports 20100801 |
| The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. | PLoS medicine 20100801 |
| Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. | Viruses 20100801 |
| Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. | AIDS (London, England) 20100717 |
| Dynamic calibration of pharmacokinetic parameters in dose-finding studies. | Biostatistics (Oxford, England) 20100701 |
| Evolving neural network optimization of cholesteryl ester separation by reversed-phase HPLC. | Analytical and bioanalytical chemistry 20100701 |
| Role of Gag in HIV Resistance to Protease Inhibitors. | Viruses 20100701 |
| Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. | Journal of pharmaceutical sciences 20100601 |
| Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. | HIV medicine 20100501 |
| Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction. | Drug metabolism and disposition: the biological fate of chemicals 20100501 |
| Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. | Journal of virology 20100501 |
| When to start antiretroviral therapy. | Current HIV/AIDS reports 20100501 |
| Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. | British journal of cancer 20100427 |
| Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20100401 |
| Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. | Drug safety 20100401 |
| Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. | The new microbiologica 20100401 |
| Diagnostic examination of the child with urolithiasis or nephrocalcinosis. | Pediatric nephrology (Berlin, Germany) 20100301 |
| Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis. | Drug development and industrial pharmacy 20100301 |
| The impact of societal changes on patterns of urolithiasis. | Current opinion in urology 20100301 |
| Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. | Xenobiotica; the fate of foreign compounds in biological systems 20100301 |
| Abstracts of the 16th Annual Society on NeuroImmune Pharmacology (SNIP) Conference. April 13-17, 2010. Manhattan Beach, California, USA. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100301 |
| Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. | Biopharmaceutics & drug disposition 20100301 |
| Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes. | PLoS neglected tropical diseases 20100301 |
| Drug-class specific impact of antivirals on the reproductive capacity of HIV. | PLoS computational biology 20100301 |
| Specification of covariance structure in longitudinal data analysis for randomized clinical trials. | Statistics in medicine 20100220 |
| HIV infection of the male genital tract--consequences for sexual transmission and reproduction. | International journal of andrology 20100201 |
| HIV protease inhibitors block oral epithelial cell DNA synthesis. | Archives of oral biology 20100201 |
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. | The Journal of infectious diseases 20100201 |
| Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. | PLoS pathogens 20100201 |
| HIV Genetic Diversity and Drug Resistance. | Viruses 20100201 |
| HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. | Journal of medicinal chemistry 20100128 |
| Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. | AIDS (London, England) 20100102 |
| Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. | Drug metabolism and disposition: the biological fate of chemicals 20100101 |
| Optical and X-ray fluorescence spectroscopy studies of bone and teeth in newborn rats after maternal treatment with indinavir. | Photochemistry and photobiology 20100101 |
| Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. | Journal of molecular graphics & modelling 20100101 |
| Antiretroviral medications: adverse effects on the kidney. | Advances in chronic kidney disease 20100101 |
| Modelling imperfect adherence to HIV induction therapy. | BMC infectious diseases 20100101 |
| HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro. | The American journal of tropical medicine and hygiene 20100101 |
| Mode of antiviral action of silver nanoparticles against HIV-1. | Journal of nanobiotechnology 20100101 |
| Profile of etravirine for the treatment of HIV infection. | Therapeutics and clinical risk management 20100101 |
| Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers. | Intervirology 20100101 |
| Technology Development Through Pooling ARV Drug Patents: A Vision from China. | The open AIDS journal 20100101 |
| [The maturation steps of human immunodeficiency virus and the role of proteolysis]. | Voprosy virusologii 20100101 |
| Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. | PloS one 20100101 |
| Increasing rates of obesity among HIV-infected persons during the HIV epidemic. | PloS one 20100101 |
| [Urologic complications of HIV infection]. | Casopis lekaru ceskych 20100101 |
| Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. | European journal of medical research 20100101 |
| Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. | BMJ (Clinical research ed.) 20100101 |
| Kidney function of HIV-infected children in Lagos, Nigeria: using Filler's serum cystatin C-based formula. | Journal of the International AIDS Society 20100101 |
| Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. | PloS one 20100101 |
| Semen may harbor HIV despite effective HAART: another piece in the puzzle. | PloS one 20100101 |
| Recent key advances in human immunodeficiency virus medicine and implications for China. | AIDS research and therapy 20100101 |
| Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. | AIDS research and therapy 20100101 |
| Dynamics of lamin-A processing following precursor accumulation. | PloS one 20100101 |
| Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. | PloS one 20100101 |
| An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells. | PloS one 20100101 |
| Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. | PloS one 20100101 |
| Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. | PloS one 20100101 |
| A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. | PloS one 20100101 |
| Co-lethality studied as an asset against viral drug escape: the HIV protease case. | Biology direct 20100101 |
| Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. | AIDS research and therapy 20100101 |
| Development of a liposomal nanodelivery system for nevirapine. | Journal of biomedical science 20100101 |
| Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. | PloS one 20100101 |
| Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study. | AIDS research and therapy 20100101 |
| Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells. | AIDS research and therapy 20100101 |
| Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. | PloS one 20100101 |
| Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). | AIDS research and therapy 20100101 |
| Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. | BMC gastroenterology 20100101 |
| Sexual assault: a report on human immunodeficiency virus postexposure prophylaxis. | Obstetrics and gynecology international 20100101 |
| Specific eradication of HIV-1 from infected cultured cells. | AIDS research and therapy 20100101 |
| Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. | Retrovirology 20100101 |
| Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine. | Retrovirology 20100101 |
| Effect of cAMP derivates on assembly and maintenance of tight junctions in human umbilical vein endothelial cells. | BMC cell biology 20100101 |
| Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. | PloS one 20100101 |
| Assessing the performance of a computer-based policy model of HIV and AIDS. | PloS one 20100101 |
| Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association 'Espoir Vie Togo' in Togo, West Africa. | BMC clinical pharmacology 20100101 |
| Emerging treatments in the management of schizophrenia - focus on sertindole. | Drug design, development and therapy 20100101 |
| Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. | Clinical epidemiology 20100101 |
| Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. | Retrovirology 20100101 |
| Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. | European journal of medical research 20100101 |
| Progress in antiretroviral drug delivery using nanotechnology. | International journal of nanomedicine 20100101 |
| Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. | PloS one 20100101 |
| Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. | PloS one 20100101 |
| Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function. | Bioinformation 20100101 |
| Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia. | AIDS research and therapy 20100101 |
| Drug interaction and pharmacist. | Journal of young pharmacists : JYP 20100101 |
| Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20100101 |
| Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. | PloS one 20100101 |
| Models of RNA virus evolution and their roles in vaccine design. | Immunome research 20100101 |
| In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. | Antiviral therapy 20100101 |
| Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. | Journal of visualized experiments : JoVE 20100101 |
| Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. | BMC infectious diseases 20100101 |
| Criticality of timing for anti-HIV therapy initiation. | PloS one 20100101 |
| A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. | HIV clinical trials 20100101 |
| Saxagliptin for type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients. | AIDS research and treatment 20100101 |
| Secondary prevention by enhancing adherence in diabetic patients. | International journal of preventive medicine 20100101 |
| Update on the diagnosis and management of acute kidney injury. | International journal of nephrology and renovascular disease 20100101 |
| HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. | Mediterranean journal of hematology and infectious diseases 20100101 |
| HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| An update on the use of Atripla in the treatment of HIV in the United States. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| New and emerging agents in the management of lipodystrophy in HIV-infected patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Oral manifestations of HIV. | Contemporary clinical dentistry 20100101 |
| Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. | Journal of blood medicine 20100101 |
| Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091215 |
| Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. | Journal of medicinal chemistry 20091210 |
| Validation of a sensitive ion chromatography method for determination of monoethylsulfate in Indinavir sulfate drug substance. | Journal of pharmaceutical and biomedical analysis 20091205 |
| Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine. | Journal of pharmaceutical and biomedical analysis 20091205 |
| Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. | Laboratory investigation; a journal of technical methods and pathology 20091201 |
| Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. | The AAPS journal 20091201 |
| Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. | Therapeutic drug monitoring 20091201 |
| Diketopiperazines from the Cordyceps-colonizing fungus Epicoccum nigrum. | Journal of natural products 20091201 |
| Impact of stimulatory pathways on adipogenesis and HIV-therapy associated lipoatrophy. | Experimental biology and medicine (Maywood, N.J.) 20091201 |
| NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. | Nanomedicine (London, England) 20091201 |
| Trends in nephropathy among HIV-infected patients. | Journal of the National Medical Association 20091201 |
| Potential of ezetimibe in memory deficits associated with dementia of Alzheimer's type in mice. | Indian journal of pharmacology 20091201 |
| HIV-1 Protease: Structural Perspectives on Drug Resistance. | Viruses 20091201 |
| Current and Novel Inhibitors of HIV Protease. | Viruses 20091201 |
| How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. | AIDS (London, England) 20091113 |
| Medical treatment of pediatric urolithiasis. | Pediatric nephrology (Berlin, Germany) 20091101 |
| Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. | The Journal of antimicrobial chemotherapy 20091101 |
| Efavirenz: a decade of clinical experience in the treatment of HIV. | The Journal of antimicrobial chemotherapy 20091101 |
| The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. | Journal of medical virology 20091001 |
| A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001 |
| The nephrotoxic effects of HAART. | Nature reviews. Nephrology 20091001 |
| Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. | PLoS computational biology 20091001 |
| The role of transporters in the pharmacokinetics of orally administered drugs. | Pharmaceutical research 20090901 |
| Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. | American journal of physiology. Regulatory, integrative and comparative physiology 20090901 |
| Role of protease inhibitors and acylation stimulating protein in the adipogenesis in 3T3-L1 cells. | Journal of veterinary science 20090901 |
| The history of antiretrovirals: key discoveries over the past 25 years. | Reviews in medical virology 20090901 |
| Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. | Journal of acquired immune deficiency syndromes (1999) 20090901 |
| [Cardiovascular risk factors associated with antiretroviral therapy]. | Enfermedades infecciosas y microbiologia clinica 20090901 |
| Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. | Life sciences 20090812 |
| Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. | Medical microbiology and immunology 20090801 |
| Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. | Biochemical and biophysical research communications 20090717 |
| Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20090709 |
| Spectrum of chronic kidney disease in HIV-infected patients. | HIV medicine 20090701 |
| Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. | Antimicrobial agents and chemotherapy 20090701 |
| The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20090701 |
| Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. | European journal of clinical pharmacology 20090701 |
| Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. | Journal of immunology (Baltimore, Md. : 1950) 20090701 |
| Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. | The Pediatric infectious disease journal 20090701 |
| HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. | Toxicology letters 20090622 |
| Effectiveness of commercial inhibitors against subtype F HIV-1 protease. | Journal of enzyme inhibition and medicinal chemistry 20090601 |
| Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. | The Journal of antimicrobial chemotherapy 20090601 |
| Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus. | Journal of medical virology 20090601 |
| HIV infection and the central nervous system: a primer. | Neuropsychology review 20090601 |
| Rapid screening and characterization of drug metabolites using multiple ion monitoring dependent product ion scan and postacquisition data mining on a hybrid triple quadrupole-linear ion trap mass spectrometer. | Rapid communications in mass spectrometry : RCM 20090601 |
| Epigenetic regulation of HIV-1 latency by cytosine methylation. | PLoS pathogens 20090601 |
| Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. | Proteins 20090515 |
| Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. | Journal of pharmaceutical sciences 20090501 |
| The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. | Antiviral research 20090501 |
| Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport. | Drug metabolism and disposition: the biological fate of chemicals 20090501 |
| Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. | Journal of hepatology 20090501 |
| Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. | Lancet (London, England) 20090418 |
| Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography. | Journal of chromatography. A 20090417 |
| Artificial neural networks in analysis of indinavir and its degradation products retention. | Talanta 20090415 |
| Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. | Bioorganic & medicinal chemistry 20090415 |
| Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. | International journal of antimicrobial agents 20090401 |
| GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. | Antimicrobial agents and chemotherapy 20090301 |
| Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. | AAPS PharmSciTech 20090301 |
| Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. | The Journal of antimicrobial chemotherapy 20090301 |
| Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20090301 |
| Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. | The American journal of pathology 20090301 |
| Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. | Anesthesiology 20090301 |
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. | PLoS pathogens 20090301 |
| Novel therapeutic biosensor for indinavir-a protease inhibitor antiretroviral drug. | Journal of pharmaceutical and biomedical analysis 20090220 |
| Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. | AIDS (London, England) 20090220 |
| Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. | AIDS (London, England) 20090220 |
| Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090215 |
| Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215 |
| Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. | Laboratory investigation; a journal of technical methods and pathology 20090201 |
| Recent developments in HIV and the kidney. | Current opinion in infectious diseases 20090201 |
| [Atazanavir-induced nephrolithiasis]. | Enfermedades infecciosas y microbiologia clinica 20090201 |
| Role of NEDD8 in HIV-associated lipodystrophy. | Differentiation; research in biological diversity 20090201 |
| HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. | AIDS (London, England) 20090128 |
| Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. | Journal of pharmaceutical sciences 20090101 |
| Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. | Clinical chemistry 20090101 |
| Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. | Pharmacology 20090101 |
| WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. | The American journal of pathology 20090101 |
| Anti-HIV drugs for cancer therapeutics: back to the future? | The Lancet. Oncology 20090101 |
| Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways. | PPAR research 20090101 |
| Urologic complications of HIV and AIDS. | Nature clinical practice. Urology 20090101 |
| Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. | Clinical drug investigation 20090101 |
| Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. | PloS one 20090101 |
| Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? | AIDS research and therapy 20090101 |
| Creatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study. | PloS one 20090101 |
| Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors. | Retrovirology 20090101 |
| Darunavir: a review of its use in the management of HIV infection in adults. | Drugs 20090101 |
| HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. | PloS one 20090101 |
| Anx2 interacts with HIV-1 Gag at phosphatidylinositol (4,5) bisphosphate-containing lipid rafts and increases viral production in 293T cells. | PloS one 20090101 |
| Is PPARγ a prospective player in HIV-1-associated bone disease? | PPAR research 20090101 |
| A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). | AIDS research and therapy 20090101 |
| PPAR and liver injury in HIV-infected patients. | PPAR research 20090101 |
| Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. | BMJ (Clinical research ed.) 20090101 |
| Role of atazanavir in the treatment of HIV infection. | Therapeutics and clinical risk management 20090101 |
| Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. | PloS one 20090101 |
| Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. | BMC infectious diseases 20090101 |
| Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy. | The open AIDS journal 20090101 |
| Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. | PloS one 20090101 |
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. | PloS one 20090101 |
| The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. | Antiviral therapy 20090101 |
| The y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stability. | PloS one 20090101 |
| Supporting children to adhere to anti-retroviral therapy in urban Malawi: multi method insights. | BMC pediatrics 20090101 |
| Host sequence motifs shared by HIV predict response to antiretroviral therapy. | BMC medical genomics 20090101 |
| The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study. | Interdisciplinary perspectives on infectious diseases 20090101 |
| Management of invasive aspergillosis in patients with COPD: rational use of voriconazole. | International journal of chronic obstructive pulmonary disease 20090101 |
| Pharmacotherapy of pediatric and adolescent HIV infection. | Therapeutics and clinical risk management 20090101 |
| Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. | Therapeutics and clinical risk management 20090101 |
| Interactions between herbal medicines and prescribed drugs: an updated systematic review. | Drugs 20090101 |
| HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management. | BMC urology 20090101 |
| Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease. | BMC bioinformatics 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. | Diabetology & metabolic syndrome 20090101 |
| Vertebral compression fractures in an HIV-positive patient with steroid-induced Cushing syndrome: a case report. | Cases journal 20090101 |
| Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. | Journal of medical case reports 20090101 |
| Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy. | BMC infectious diseases 20090101 |
| Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. | Journal of biomedicine & biotechnology 20090101 |
| RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. | AIDS research and therapy 20090101 |
| The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia. | The open virology journal 20090101 |
| Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. | BMC public health 20090101 |
| Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: a mathematical approach. | BMC public health 20090101 |
| German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. | European journal of medical research 20090101 |
| Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. | Obstetrics and gynecology international 20090101 |
| Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. | BMC infectious diseases 20090101 |
| Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. | AIDS research and therapy 20090101 |
| Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. | PloS one 20090101 |
| Conivaptan and its role in the treatment of hyponatremia. | Drug design, development and therapy 20090101 |
| Disfiguring molluscum contagiosum in a HIV-positive patient responding to antiretroviral therapy. | Indian journal of dermatology 20090101 |
| A comprehensive review of immunosuppression used for liver transplantation. | Journal of transplantation 20090101 |
| Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. | Infectious diseases in obstetrics and gynecology 20090101 |
| Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. | The open AIDS journal 20090101 |
| Conivaptan: Evidence supporting its therapeutic use in hyponatremia. | Core evidence 20090101 |
| Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy. | F1000 medicine reports 20090101 |
| Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. | Journal of medical case reports 20090101 |
| Pharmacotherapeutic options for visceral leishmaniasis-current scenario. | Clinical medicine. Pathology 20090101 |
| Profile of darunavir in the management of treatment-experienced HIV patients. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Role of darunavir in the management of HIV infection. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. | Therapeutic drug monitoring 20081201 |
| P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate? | The AAPS journal 20081201 |
| Using AutoDock for ligand-receptor docking. | Current protocols in bioinformatics 20081201 |
| Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients. | Therapeutics and clinical risk management 20081201 |
| Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. | Xenobiotica; the fate of foreign compounds in biological systems 20081101 |
| Pestalazines and pestalamides, bioactive metabolites from the plant pathogenic fungus Pestalotiopsis theae. | Journal of natural products 20081101 |
| HIV pharmacogenetics in clinical practice: recent achievements and future challenges. | Current HIV research 20081101 |
| Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. | Bioorganic & medicinal chemistry letters 20081015 |
| Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20081009 |
| Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. | Journal of medicinal chemistry 20081009 |
| Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. | The Journal of antimicrobial chemotherapy 20081001 |
| Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. | Therapeutics and clinical risk management 20081001 |
| Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode. | Analytical chemistry 20080915 |
| Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. | Biochemical and biophysical research communications 20080912 |
| The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. | AIDS (London, England) 20080912 |
| Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. | Journal of pharmaceutical sciences 20080901 |
| A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. | Antiviral research 20080901 |
| Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases. | Journal of chemical information and modeling 20080901 |
| A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrations. | Analytica chimica acta 20080815 |
| No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080815 |
| Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. | Journal of medicinal chemistry 20080814 |
| Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. | British journal of clinical pharmacology 20080801 |
| Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa. | Journal of clinical pharmacy and therapeutics 20080801 |
| Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. | Therapeutic drug monitoring 20080801 |
| The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus--potential role in modulation of glucose uptake in neurones? | The European journal of neuroscience 20080801 |
| Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy. | Journal of Korean medical science 20080801 |
| Combating HIV resistance - focus on darunavir. | Therapeutics and clinical risk management 20080801 |
| The Relationship Between HIV Infection and Cardiovascular Disease. | Current cardiology reviews 20080801 |
| Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. | Virology 20080720 |
| Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. | European journal of medicinal chemistry 20080701 |
| Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20080701 |
| A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand. | Journal of virological methods 20080701 |
| Quantitative analysis of antiretroviral drugs in lysates of peripheral blood mononuclear cells using MALDI-triple quadrupole mass spectrometry. | Analytical chemistry 20080701 |
| Profiling resistance-related mutations in the protease region of the pol gene: single genome sequencing of HIV in plasma and peripheral blood mononuclear cells. | AIDS research and human retroviruses 20080701 |
| Improved synthesis and pharmacological evaluation of racemic 11 -demethylcalanolide A. | Yao xue xue bao = Acta pharmaceutica Sinica 20080701 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| Evaluation of thermal stability of indinavir sulphate using diffuse reflectance infrared spectroscopy. | Journal of pharmaceutical and biomedical analysis 20080609 |
| Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. | British journal of cancer 20080603 |
| Quality control of protease inhibitors. | Journal of pharmaceutical sciences 20080601 |
| Effect of semen sampling frequency on seminal antiretroviral drug concentration. | Clinical pharmacology and therapeutics 20080601 |
| [Bilateral papillary necrosis during indinavir treatment]. | Presse medicale (Paris, France : 1983) 20080601 |
| Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. | Pharmacology, biochemistry, and behavior 20080601 |
| Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. | Antimicrobial agents and chemotherapy 20080601 |
| Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. | The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20080601 |
| [Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors]. | Arquivos brasileiros de endocrinologia e metabologia 20080601 |
| Atriplatrade mark - HIV therapy in one pill. | Therapeutics and clinical risk management 20080601 |
| Renal manifestations in HIV-infected Jamaican children. | The West Indian medical journal 20080601 |
| Analysis of correlated mutations in HIV-1 protease using spectral clustering. | Bioinformatics (Oxford, England) 20080515 |
| Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry. | Analytical chemistry 20080515 |
| Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis. | Journal of ethnopharmacology 20080508 |
| Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. | British journal of clinical pharmacology 20080501 |
| Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. | Journal of leukocyte biology 20080501 |
| Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. | Journal of acquired immune deficiency syndromes (1999) 20080501 |
| [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)]. | Medecine et maladies infectieuses 20080501 |
| [Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs]. | Enfermedades infecciosas y microbiologia clinica 20080501 |
| Acute human immunodeficiency virus syndrome presenting with hemophagocytic lymphohistiocytosis. | Yonsei medical journal 20080430 |
| Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. | Journal of computational chemistry 20080415 |
| Chloropupukeananin, the first chlorinated pupukeanane derivative, and its precursors from Pestalotiopsis fici. | Organic letters 20080403 |
| Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. | Antimicrobial agents and chemotherapy 20080401 |
| Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. | Chemical biology & drug design 20080401 |
| [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo]. | Bulletin de la Societe de pathologie exotique (1990) 20080401 |
| Conivaptan: a step forward in the treatment of hyponatremia? | Therapeutics and clinical risk management 20080401 |
| 'One pill, once daily': what clinicians need to know about Atriplatrade mark. | Therapeutics and clinical risk management 20080401 |
| Association of antiretroviral therapy with fibrinogen levels in HIV-infection. | AIDS (London, England) 20080330 |
| Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. | Biopharmaceutics & drug disposition 20080301 |
| HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. | American journal of physiology. Endocrinology and metabolism 20080301 |
| Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. | Cardiovascular toxicology 20080301 |
| Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301 |
| Drug-induced crystal nephropathy: an update. | Expert opinion on drug safety 20080301 |
| Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. | The AAPS journal 20080301 |
| Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic. | Journal of medicinal chemistry 20080227 |
| pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. | Journal of pharmaceutical sciences 20080201 |
| An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. | Journal of mass spectrometry : JMS 20080201 |
| Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure. | Bioorganic & medicinal chemistry 20080201 |
| Prevalence of chronic kidney disease in an urban HIV infected population. | The American journal of the medical sciences 20080201 |
| HIV therapy, metabolic syndrome, and cardiovascular risk. | Current atherosclerosis reports 20080201 |
| Indinavir-associated toxicity mimicking urinary tuberculosis in a patient with AIDS. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20080201 |
| Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). | Therapeutics and clinical risk management 20080201 |
| The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. | Biochemistry 20080115 |
| Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. | AIDS (London, England) 20080111 |
| Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. | Journal of clinical epidemiology 20080101 |
| Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. | European journal of dermatology : EJD 20080101 |
| Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. | Pharmacotherapy 20080101 |
| Two immunomodulators, curcumin and sulfasalazine, enhance IDV antiretroviral activity in HIV-1 persistently infected cells. | Archives of virology 20080101 |
| Oral adverse effects due to the use of Nevirapine. | The journal of contemporary dental practice 20080101 |
| Drug interactions between HIV protease inhibitors and acid-reducing agents. | Clinical pharmacokinetics 20080101 |
| Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. | HIV clinical trials 20080101 |
| Application of rat in situ single-pass intestinal perfusion in the evaluation of presystemic extraction of indinavir under different perfusion rates. | Journal of the Formosan Medical Association = Taiwan yi zhi 20080101 |
| Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. | Retrovirology 20080101 |
| Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. | Annals of clinical microbiology and antimicrobials 20080101 |
| The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. | Retrovirology 20080101 |
| Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. | Retrovirology 20080101 |
| Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement. | Journal of neurovirology 20080101 |
| Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. | BMC neuroscience 20080101 |
| Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. | Globalization and health 20080101 |
| Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy. | Retrovirology 20080101 |
| Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. | PloS one 20080101 |
| High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. | World journal of surgical oncology 20080101 |
| Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. | Molecular pain 20080101 |
| Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. | AIDS research and therapy 20080101 |
| Proteochemometric modeling of HIV protease susceptibility. | BMC bioinformatics 20080101 |
| [Urinary lithiasis secondary to medication in HIV+ patients receiving Indinavir]. | Archivos espanoles de urologia 20080101 |
| Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. | PloS one 20080101 |
| Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. | PloS one 20080101 |
| Three new derivatives of anti-HIV-1 polyphenols isolated from Salvia yunnanensis. | Journal of Asian natural products research 20080101 |
| Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. | Acta poloniae pharmaceutica 20080101 |
| An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. | PloS one 20080101 |
| Viral complementation allows HIV-1 replication without integration. | Retrovirology 20080101 |
| Clinically relevant safety issues associated with St. John's wort product labels. | BMC complementary and alternative medicine 20080101 |
| Clinical drugs that interact with St. John's wort and implication in drug development. | Current pharmaceutical design 20080101 |
| Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome. | Indian journal of ophthalmology 20080101 |
| Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. | BMC complementary and alternative medicine 20080101 |
| Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. | PloS one 20080101 |
| High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in Pune, India. | BMC infectious diseases 20080101 |
| Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. | BMC infectious diseases 20080101 |
| A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. | Drug metabolism and pharmacokinetics 20080101 |
| 25 years of HIV-1 research - progress and perspectives. | BMC medicine 20080101 |
| Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. | Journal of biopharmaceutical statistics 20080101 |
| Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. | Journal of medical case reports 20080101 |
| Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. | PloS one 20080101 |
| The experiential health information processing model: supporting collaborative web-based patient education. | BMC medical informatics and decision making 20080101 |
| PocketMatch: a new algorithm to compare binding sites in protein structures. | BMC bioinformatics 20080101 |
| Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. | PloS one 20080101 |
| Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. | Retrovirology 20080101 |
| Cell engineering and molecular pharming for biopharmaceuticals. | The open medicinal chemistry journal 20080101 |
| Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina. | Journal of the International AIDS Society 20080101 |
| Raltegravir in the management of HIV-infected patients. | Drug design, development and therapy 20080101 |
| [Dietary recommendations with practical examples of menus for people living with HIV/AIDS in sub-Saharan Africa]. | The Pan African medical journal 20080101 |
| Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005. | The Pan African medical journal 20080101 |
| Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | The Journal of antimicrobial chemotherapy 20071201 |
| [Indinavir-associated tubulointerstitial renal disease]. | Nephrologie & therapeutique 20071201 |
| Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. | AIDS patient care and STDs 20071201 |
| Obstructive uropathy in a HIV+ infant under indinavir treatment. | Journal of pediatric urology 20071201 |
| The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model. | Statistics in medicine 20071130 |
| HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115 |
| Prevalence of chronic kidney disease in Chinese HIV-infected patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071101 |
| Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. | European journal of clinical pharmacology 20071101 |
| Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. | Basic & clinical pharmacology & toxicology 20071101 |
| Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. | PLoS medicine 20071101 |
| An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. | PLoS computational biology 20071101 |
| Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. | Clinical therapeutics 20071101 |
| Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. | AIDS (London, England) 20071018 |
| Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. | Biomedical chromatography : BMC 20071001 |
| Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. | Cell death and differentiation 20071001 |
| Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. | The Journal of antimicrobial chemotherapy 20071001 |
| HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. | Toxicology and applied pharmacology 20071001 |
| Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity. | European journal of clinical pharmacology 20071001 |
| Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus. | Bioorganic & medicinal chemistry letters 20071001 |
| Prevalence and factors associated with dry skin in HIV infection: the FRAM study. | AIDS (London, England) 20071001 |
| A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. | Tropical medicine & international health : TM & IH 20071001 |
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. | The Journal of biological chemistry 20070928 |
| Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915 |
| Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20070901 |
| Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. | British journal of clinical pharmacology 20070901 |
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. | Antimicrobial agents and chemotherapy 20070901 |
| Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. | HIV medicine 20070901 |
| Mycobacterium avium complex infection presenting as an endobronchial mass in a patient with acquired immune deficiency syndrome. | The Korean journal of internal medicine 20070901 |
| [Three patients with indinavir-related urolithiasis]. | Nederlands tijdschrift voor geneeskunde 20070818 |
| Identification and characterization of an aspartyl protease from Cryptococcus neoformans. | FEBS letters 20070807 |
| Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study. | Journal of acquired immune deficiency syndromes (1999) 20070801 |
| Hair loss induced by lopinavir-ritonavir. | Pharmacotherapy 20070801 |
| Identification of drugs that interact with herbs in drug development. | Drug discovery today 20070801 |
| Central nervous system distribution kinetics of indinavir in rats. | The Journal of pharmacy and pharmacology 20070801 |
| The renaissance of fixed dose combinations: Combivir. | Therapeutics and clinical risk management 20070801 |
| Review of tipranavir in the treatment of drug-resistant HIV. | Therapeutics and clinical risk management 20070801 |
| Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring. | European journal of medical research 20070726 |
| Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. | AIDS (London, England) 20070701 |
| Optimal timing and duration of induction therapy for HIV-1 infection. | PLoS computational biology 20070701 |
| Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. | Journal of drugs in dermatology : JDD 20070701 |
| [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy]. | Mikrobiyoloji bulteni 20070701 |
| The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. | AIDS (London, England) 20070619 |
| Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601 |
| Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. | Hematological oncology 20070601 |
| A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. | Antimicrobial agents and chemotherapy 20070601 |
| HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA. | Biochemical pharmacology 20070601 |
| Therapeutic issues in HIV/HCV-coinfected patients. | Journal of viral hepatitis 20070601 |
| Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. | Infection control and hospital epidemiology 20070601 |
| Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. | Expert opinion on drug metabolism & toxicology 20070601 |
| Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. | Infection 20070601 |
| Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. | Metabolic syndrome and related disorders 20070601 |
| Chronic renal failure among HIV-1-infected patients. | AIDS (London, England) 20070531 |
| A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. | Neurology 20070529 |
| Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| Nephrotoxicity of antiretroviral therapy in an HIV-infected patient. | Kidney international 20070501 |
| Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? | Expert opinion on pharmacotherapy 20070501 |
| Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells. | Mycoses 20070501 |
| Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. | Biological & pharmaceutical bulletin 20070501 |
| Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. | Current drug safety 20070501 |
| Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070401 |
| An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease. | Acta crystallographica. Section F, Structural biology and crystallization communications 20070401 |
| ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. | PLoS pathogens 20070401 |
| Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. | Therapeutic drug monitoring 20070401 |
| Drug reactions affecting the nail unit: diagnosis and management. | Dermatologic clinics 20070401 |
| High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. | Journal of pharmaceutical and biomedical analysis 20070312 |
| Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. | British journal of clinical pharmacology 20070301 |
| Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. | Expert opinion on pharmacotherapy 20070301 |
| Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070301 |
| Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. | PLoS medicine 20070301 |
| Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. | PLoS clinical trials 20070301 |
| Progressive outer retinal necrosis combined with vitreous hemorrhage in a patient with acquired immunodeficiency syndrome. | Korean journal of ophthalmology : KJO 20070301 |
| [Indinavir stones]. | Actas urologicas espanolas 20070301 |
| Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20070301 |
| Venlafaxine extended release (XR) in the treatment of panic disorder. | Therapeutics and clinical risk management 20070301 |
| Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. | Virology 20070205 |
| Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. | Journal of pharmacokinetics and pharmacodynamics 20070201 |
| Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. | The Journal of antimicrobial chemotherapy 20070201 |
| Less sensitive HIV-1 enzyme immunoassay as an adjuvant method for monitoring patients receiving antiretroviral therapy. | AIDS patient care and STDs 20070201 |
| HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. | AIDS research and human retroviruses 20070201 |
| Venlafaxine in the treatment of panic disorder. | Neuropsychiatric disease and treatment 20070201 |
| Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. | The Cochrane database of systematic reviews 20070124 |
| Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. | AIDS (London, England) 20070102 |
| Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice. | American journal of physiology. Endocrinology and metabolism 20070101 |
| Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101 |
| In silico prediction of pregnane X receptor activators by machine learning approaches. | Molecular pharmacology 20070101 |
| Influence of body temperature on indinavir crystallization under loop of Henle conditions. | The Journal of antimicrobial chemotherapy 20070101 |
| Urological management of indinavir-associated acute renal failure in HIV-positive patients. | International urology and nephrology 20070101 |
| Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. | The Pediatric infectious disease journal 20070101 |
| The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. | PloS one 20070101 |
| A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. | PLoS medicine 20070101 |
| Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. | AIDS research and human retroviruses 20070101 |
| Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire. | AIDS research and human retroviruses 20070101 |
| Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report. | AIDS research and therapy 20070101 |
| Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. | AIDS research and therapy 20070101 |
| Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivity. | Retrovirology 20070101 |
| HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? | PloS one 20070101 |
| MSE with mass defect filtering for in vitro and in vivo metabolite identification. | Rapid communications in mass spectrometry : RCM 20070101 |
| Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. | Arzneimittel-Forschung 20070101 |
| Gender-specific effects of HIV protease inhibitors on body mass in mice. | AIDS research and therapy 20070101 |
| Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. | BMC infectious diseases 20070101 |
| Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. | Journal of medical case reports 20070101 |
| TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? | Globalization and health 20070101 |
| AIDS in the Third World: how to stop the HIV infection? | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Anti-HIV drugs. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. | BMC infectious diseases 20070101 |
| HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms. | AIDS research and therapy 20070101 |
| Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20070101 |
| Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. | AIDS research and therapy 20070101 |
| HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. | AIDS research and therapy 20070101 |
| Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. | Rapid communications in mass spectrometry : RCM 20070101 |
| Dermatologic adverse effects of antiretroviral therapy: recognition and management. | American journal of clinical dermatology 20070101 |
| A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. | PloS one 20070101 |
| Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. | PloS one 20070101 |
| Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. | Antiviral therapy 20070101 |
| Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. | Reproductive toxicology (Elmsford, N.Y.) 20070101 |
| Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. | Scandinavian journal of infectious diseases 20070101 |
| Characterization of the invariable residue 51 mutations of human immunodeficiency virus type 1 capsid protein on in vitro CA assembly and infectivity. | Retrovirology 20070101 |
| Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. | Antiviral therapy 20070101 |
| Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005. | AIDS research and therapy 20070101 |
| Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection. | HIV clinical trials 20070101 |
| Poor follow-up rates at a self-pay northern Indian tertiary AIDS clinic. | International journal for equity in health 20070101 |
| Medicinal importance of grapefruit juice and its interaction with various drugs. | Nutrition journal 20070101 |
| Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. | Cost effectiveness and resource allocation : C/E 20070101 |
| Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. | Current medicinal chemistry 20070101 |
| Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101 |
| Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. | BMC infectious diseases 20070101 |
| Morphological and biochemical appraisal of the liver and renal effects of indinavir on rat pregnancy. | Clinical and experimental obstetrics & gynecology 20070101 |
| Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. | Antiviral therapy 20070101 |
| Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy. | The open virology journal 20070101 |
| Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. | Journal of the International AIDS Society 20070101 |
| Maraviroc: the evidence for its potential in the management of HIV. | Core evidence 20070101 |
| Phenotypic resistance of resistant strains of HIV type-1 subtype B in China. | Chinese medical journal 20061205 |
| Antiviral activity of Arthrospira-derived spirulan-like substances. | Antiviral research 20061201 |
| Indinavir crystalluria. | Kidney international 20061201 |
| Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. | PLoS medicine 20061201 |
| Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. | Journal of leukocyte biology 20061101 |
| Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors. | Research in microbiology 20061101 |
| Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). | Journal of acquired immune deficiency syndromes (1999) 20061101 |
| Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma. | International journal of STD & AIDS 20061101 |
| Acid suppressive therapy and the effects on protease inhibitors. | The Annals of pharmacotherapy 20061101 |
| Atazanavir urinary stones in an HIV-infected patient. | AIDS (London, England) 20061024 |
| Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. | Blood 20061015 |
| Insulin sensitivity is preserved despite disrupted endothelial function. | American journal of physiology. Endocrinology and metabolism 20061001 |
| Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. | Clinical pharmacology and therapeutics 20061001 |
| Viral and latent reservoir persistence in HIV-1-infected patients on therapy. | PLoS computational biology 20061001 |
| Evaluation of an International Pharmacopoeia method for the analysis of indinavir sulfate by liquid chromatography. | Journal of pharmaceutical and biomedical analysis 20060911 |
| Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up. | Journal of acquired immune deficiency syndromes (1999) 20060901 |
| Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. | The Journal of infectious diseases 20060901 |
| Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. | Anti-cancer drugs 20060901 |
| Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. | PLoS medicine 20060901 |
| Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. | Journal of medicinal chemistry 20060824 |
| Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. | AIDS (London, England) 20060822 |
| Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. | Journal of pharmacokinetics and pharmacodynamics 20060801 |
| Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. | The Journal of antimicrobial chemotherapy 20060801 |
| Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060801 |
| Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Role of P-glycoprotein in tissue uptake of indinavir in rat. | Life sciences 20060801 |
| Antiretrovirals induce direct endothelial dysfunction in vivo. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. | Pharmaceutical research 20060801 |
| Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. | British journal of clinical pharmacology 20060801 |
| [Central nervous system HIV-associated polyarteritis nodosa: long-term outcome]. | La Revue de medecine interne 20060801 |
| Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe. | Pharmacotherapy 20060801 |
| Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. | Therapeutic drug monitoring 20060801 |
| Alcohol and indinavir adversely affect protein synthesis and phosphorylation of MAPK and mTOR signaling pathways in C2C12 myocytes. | Alcoholism, clinical and experimental research 20060801 |
| Urinary NO3 excretion and renal failure in indinavir-treated patients. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20060801 |
| High prevalence of indinavir-associated renal complications in Thai HIV-infected patients. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801 |
| Drug-drug interaction between pitavastatin and various drugs via OATP1B1. | Drug metabolism and disposition: the biological fate of chemicals 20060701 |
| Nephrotoxicity as a complication of antiretroviral therapy. | Advances in chronic kidney disease 20060701 |
| DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. | PLoS pathogens 20060701 |
| Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. | PLoS pathogens 20060701 |
| A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. | PLoS clinical trials 20060701 |
| Use of HIV Postexposure Prophylaxis in healthcare workers after occupational exposure: a Thai university hospital setting. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060701 |
| Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. | HIV medicine 20060701 |
| Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. | European journal of medical research 20060630 |
| Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. | Antiviral research 20060601 |
| Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model. | Biophysical journal 20060601 |
| The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. | The Journal of antimicrobial chemotherapy 20060601 |
| Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. | Clinical chemistry 20060601 |
| The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). | Journal of acquired immune deficiency syndromes (1999) 20060601 |
| Antiretroviral drug resistance and routine therapy, Cameroon. | Emerging infectious diseases 20060601 |
| Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. | Journal of acquired immune deficiency syndromes (1999) 20060601 |
| Recent developments in drug targets and delivery of anti-HIV drugs. | Infectious disorders drug targets 20060601 |
| High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar. | AIDS research and human retroviruses 20060601 |
| Voriconazole in the management of nosocomial invasive fungal infections. | Therapeutics and clinical risk management 20060601 |
| Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. | Journal of molecular biology 20060519 |
| HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060515 |
| Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. | Biochemistry 20060502 |
| HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. | Apoptosis : an international journal on programmed cell death 20060501 |
| Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. | The Journal of general virology 20060501 |
| Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. | Pharmacogenetics and genomics 20060501 |
| Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. | Annals of neurology 20060501 |
| Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. | Journal of acquired immune deficiency syndromes (1999) 20060501 |
| Electrochemical methods for determination of the protease inhibitor indinavir sulfate in pharmaceuticals and human serum. | Die Pharmazie 20060501 |
| HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected Koreans. | Yonsei medical journal 20060430 |
| Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. | AIDS (London, England) 20060424 |
| Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. | AIDS (London, England) 20060424 |
| Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis. | AIDS (London, England) 20060424 |
| Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060415 |
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. | Bioorganic & medicinal chemistry letters 20060401 |
| Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. | The Journal of antimicrobial chemotherapy 20060401 |
| High incidence of adverse reactions to initial antiretroviral therapy in Brazil. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20060401 |
| Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. | Journal of acquired immune deficiency syndromes (1999) 20060401 |
| [Drug-induced renal calculi]. | Annales d'urologie 20060401 |
| Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. | PLoS medicine 20060301 |
| Antiretroviral therapy and dyslipidaemia: unlocking the code. | PLoS medicine 20060301 |
| Hyperforin in St. John's wort drug interactions. | European journal of clinical pharmacology 20060301 |
| In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. | Antimicrobial agents and chemotherapy 20060301 |
| Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts. | Medical mycology 20060301 |
| Simple and sensitive high-performance liquid chromatography method for the quantitation of indinavir in rat plasma and central nervous system. | Journal of separation science 20060301 |
| Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. | Journal of medicinal chemistry 20060223 |
| Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217 |
| Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains. | Bioorganic & medicinal chemistry letters 20060215 |
| LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice. | Journal of pharmaceutical and biomedical analysis 20060213 |
| Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202 |
| [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection]. | Revista clinica espanola 20060201 |
| Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. | Arzneimittel-Forschung 20060201 |
| High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. | AIDS (London, England) 20060102 |
| Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. | AIDS (London, England) 20060102 |
| Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. | Biomedical chromatography : BMC 20060101 |
| HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents. | The Journal of pharmacology and experimental therapeutics 20060101 |
| Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. | HIV medicine 20060101 |
| Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. | Clinical nephrology 20060101 |
| Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. | In vivo (Athens, Greece) 20060101 |
| Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. | Basic & clinical pharmacology & toxicology 20060101 |
| T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. | BioTechniques 20060101 |
| Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. | Annals of clinical microbiology and antimicrobials 20060101 |
| Understanding and avoiding antiretroviral adverse events. | Current pharmaceutical design 20060101 |
| Adhesive capsulitis of the shoulder in human immunodeficiency virus-positive patients during highly active antiretroviral therapy. | Journal of shoulder and elbow surgery 20060101 |
| Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma. | Clinical chemistry and laboratory medicine 20060101 |
| DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes. | BMC infectious diseases 20060101 |
| Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. | BMC infectious diseases 20060101 |
| Proteins pattern alteration in AZT-treated K562 cells detected by two-dimensional gel electrophoresis and peptide mass fingerprinting. | Proteome science 20060101 |
| Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). | Antiviral therapy 20060101 |
| Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit--a homogeneous population? | Critical care (London, England) 20060101 |
| Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART. | AIDS research and therapy 20060101 |
| Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. | Biology direct 20060101 |
| Serious renal impairment occurs rarely with use of tenofovir DF. | HIV clinical trials 20060101 |
| Therapeutic drug monitoring in HIV treatment: a literature review. | HIV clinical trials 20060101 |
| Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. | Antiviral therapy 20060101 |
| Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. | Antiviral therapy 20060101 |
| [Pneumocystis jirovecii pneumonia: an old disease with a new name]. | Medicina (Kaunas, Lithuania) 20060101 |
| Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. | Antiviral therapy 20060101 |
| Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report. | BMC infectious diseases 20060101 |
| 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. | Retrovirology 20060101 |
| Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. | Microbiology and immunology 20060101 |
| Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. | HIV clinical trials 20060101 |
| Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin. | Antiviral chemistry & chemotherapy 20060101 |
| Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. | BMC immunology 20060101 |
| Therapeutic challenges in hepatitis C-infected injection drug using patients. | Harm reduction journal 20060101 |
| Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport. | Bioconjugate chemistry 20060101 |
| An immunological comparison of third companion in advanced drug-naive HIV-infected patients. | HIV clinical trials 20060101 |
| Drug-herb interactions: eliminating toxicity with hard drug design. | Current pharmaceutical design 20060101 |
| Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. | PloS one 20060101 |
| Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. | AIDS research and therapy 20060101 |
| Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. | Cost effectiveness and resource allocation : C/E 20060101 |
| Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations. | HIV clinical trials 20060101 |
| Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). | Antiviral therapy 20060101 |
| Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. | Antiviral therapy 20060101 |
| Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors. | Bioinorganic chemistry and applications 20060101 |
| Antihuman Immunodeficiency Virus Type 1 (HIV-1) Activity of Rare Earth Metal Complexes of 4-Hydroxycoumarins in Cell Culture. | Bioinorganic chemistry and applications 20060101 |
| [Post-exposure prophylaxis of HIV infection in out-patient clinic of hospital for infectious diseases in Warsaw in 2001-2002]. | Przeglad epidemiologiczny 20060101 |
| Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. | Journal of the International AIDS Society 20060101 |
| Accidental blood exposure: risk and prevention in interventional radiology. | Biomedical imaging and intervention journal 20060101 |
| Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227 |
| Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215 |
| Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. | Journal of molecular biology 20051209 |
| Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. | AIDS (London, England) 20051202 |
| Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. | Bioorganic & medicinal chemistry letters 20051201 |
| Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. | Journal of acquired immune deficiency syndromes (1999) 20051201 |
| Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients. | Therapeutic drug monitoring 20051201 |
| Possible reduction in indinavir serum concentrations by bosentan. | Therapeutic drug monitoring 20051201 |
| Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. | European journal of clinical investigation 20051201 |
| Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. | Die Pharmazie 20051201 |
| Anti-HIV-1 activity of propolis in CD4(+) lymphocyte and microglial cell cultures. | Journal of ethnopharmacology 20051114 |
| In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. | Pharmaceutical research 20051101 |
| Immunodysregulation of HIV disease at bone marrow level. | Autoimmunity reviews 20051101 |
| Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. | HIV medicine 20051101 |
| Indinavir impairs endothelial function in healthy HIV-negative men. | American heart journal 20051101 |
| Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20051101 |
| A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. | AIDS research and human retroviruses 20051101 |
| Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. | The Journal of infectious diseases 20051015 |
| The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. | The Journal of infectious diseases 20051015 |
| HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. | AIDS (London, England) 20051014 |
| MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. | AIDS (London, England) 20051014 |
| Determination of antiretroviral agents in human serum by capillary electrophoresis. | Journal of chromatography. A 20051014 |
| Fat distribution in men with HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20051001 |
| Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. | The FEBS journal 20051001 |
| Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. | Current drug metabolism 20051001 |
| Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. | Bioorganic & medicinal chemistry letters 20050915 |
| HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. | Cancer research 20050915 |
| Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050915 |
| The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. | AIDS (London, England) 20050902 |
| Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle. | American journal of physiology. Endocrinology and metabolism 20050901 |
| HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. | Molecular pharmacology 20050901 |
| Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. | British journal of clinical pharmacology 20050901 |
| Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. | Journal of acquired immune deficiency syndromes (1999) 20050901 |
| [HIV infection, antiretroviral therapy, and endothelium]. | Herz 20050901 |
| Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors. | Bioorganic & medicinal chemistry letters 20050815 |
| GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. | Arteriosclerosis, thrombosis, and vascular biology 20050801 |
| Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. | Laboratory investigation; a journal of technical methods and pathology 20050801 |
| Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. | Bioorganic & medicinal chemistry letters 20050801 |
| TDM: therapeutic drug measuring or therapeutic drug monitoring? | Therapeutic drug monitoring 20050801 |
| Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. | Clinical pharmacology and therapeutics 20050801 |
| Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis. | The Journal of investigative dermatology 20050801 |
| Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort. | AIDS research and human retroviruses 20050801 |
| HIV associated arthritis: case report and review of the literature. | European journal of medical research 20050729 |
| Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715 |
| [Portal vein thrombosis in HIV-infected patients: report of four cases]. | La Revue de medecine interne 20050701 |
| Antileishmanial activity of HIV protease inhibitors. | International journal of antimicrobial agents 20050701 |
| Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. | AIDS (London, England) 20050701 |
| Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. | Biological & pharmaceutical bulletin 20050701 |
| Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings. | Current HIV research 20050701 |
| Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. | AIDS research and human retroviruses 20050701 |
| Predicting drug metabolism--an evaluation of the expert system METEOR. | Chemistry & biodiversity 20050701 |
| [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection]. | Presse medicale (Paris, France : 1983) 20050604 |
| [Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort]. | Presse medicale (Paris, France : 1983) 20050604 |
| Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. | Annals of neurology 20050601 |
| Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. | The Journal of antimicrobial chemotherapy 20050601 |
| Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. | Journal of acquired immune deficiency syndromes (1999) 20050601 |
| Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. | Therapeutic drug monitoring 20050601 |
| A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. | Cellular and molecular life sciences : CMLS 20050601 |
| Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. | Fundamental & clinical pharmacology 20050601 |
| Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073). | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050601 |
| TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. | Antimicrobial agents and chemotherapy 20050601 |
| Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. | Antimicrobial agents and chemotherapy 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525 |
| Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. | AIDS (London, England) 20050520 |
| Antiviral drug-induced nephrotoxicity. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20050501 |
| Hepatotoxicity and nelfinavir: a meta-analysis. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501 |
| Emerging anti-HIV drugs. | Expert opinion on emerging drugs 20050501 |
| Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050415 |
| A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. | Neurology 20050412 |
| Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. | The Journal of antimicrobial chemotherapy 20050401 |
| The urological management of the patient with acquired immunodeficiency syndrome. | BJU international 20050401 |
| Postexposure prophylaxis after sexual assaults: a prospective cohort study. | Sexually transmitted diseases 20050401 |
| Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20050401 |
| Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents. | The Journal of pharmacy and pharmacology 20050401 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. | PLoS medicine 20050401 |
| Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. | AIDS (London, England) 20050325 |
| Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. | Journal of medicinal chemistry 20050324 |
| Design of HIV-1 protease inhibitors active on multidrug-resistant virus. | Journal of medicinal chemistry 20050324 |
| [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China]. | Zhonghua yi xue za zhi 20050323 |
| Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. | European journal of clinical pharmacology 20050301 |
| Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Gender differences in health-related quality of life in patients with HIV/AIDS. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20050301 |
| Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | Therapeutics and clinical risk management 20050301 |
| Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. | AIDS (London, England) 20050218 |
| Mechanism-based inactivation of CYP3A by HIV protease inhibitors. | The Journal of pharmacology and experimental therapeutics 20050201 |
| Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. | Journal of clinical pharmacology 20050201 |
| Herb-drug interactions: an overview of the clinical evidence. | Fundamental & clinical pharmacology 20050201 |
| Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. | Therapeutic drug monitoring 20050201 |
| Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment. | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 20050201 |
| Warning about indinavir and pregnancy. | AIDS patient care and STDs 20050201 |
| Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. | Pharmacotherapy 20050201 |
| The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. | Current HIV/AIDS reports 20050201 |
| Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. | The Journal of biological chemistry 20050121 |
| Influence of indinavir on virulence and growth of Cryptococcus neoformans. | The Journal of infectious diseases 20050115 |
| Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101 |
| Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. | BMC infectious diseases 20050101 |
| No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. | Annals of clinical microbiology and antimicrobials 20050101 |
| HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients. | AIDS research and human retroviruses 20050101 |
| Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. | HIV medicine 20050101 |
| Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. | Lipids in health and disease 20050101 |
| Molecular strategies to inhibit HIV-1 replication. | Retrovirology 20050101 |
| Lymphoid tissue targeting of anti-HIV drugs using liposomes. | Methods in enzymology 20050101 |
| [Radio-opaque lithiasis and indinavir]. | Actas urologicas espanolas 20050101 |
| Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. | BMC infectious diseases 20050101 |
| Capacity building for the clinical investigation of AIDS malignancy in East Africa. | Cancer detection and prevention 20050101 |
| Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20050101 |
| Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. | Antiviral therapy 20050101 |
| The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. | Health and quality of life outcomes 20050101 |
| Herb-drug interactions: a literature review. | Drugs 20050101 |
| High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus. | BMC infectious diseases 20050101 |
| Nephrotoxicity related to new therapeutic compounds. | Renal failure 20050101 |
| Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. | BMC infectious diseases 20050101 |
| Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20050101 |
| Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. | Rapid communications in mass spectrometry : RCM 20050101 |
| HIV protease inhibitors prevent mitochondrial hyperpolarization and redox imbalance and decrease endogenous uncoupler protein-2 expression in gp 120-activated human T lymphocytes. | Antiviral therapy 20050101 |
| Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. | Antiviral therapy 20050101 |
| Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. | Journal of immune based therapies and vaccines 20050101 |
| Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report. | BMC infectious diseases 20050101 |
| ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. | Cancer cell international 20050101 |
| HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors. | AIDS research and therapy 20050101 |
| Human immunodeficiency virus type-1 episomal cDNA in semen. | AIDS research and therapy 20050101 |
| Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? | Antiviral therapy 20050101 |
| HIV in semen: still more to be learned. | AIDS research and therapy 20050101 |
| High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. | Clinical pharmacokinetics 20050101 |
| Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. | Antiviral therapy 20050101 |
| Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients. | Clinical drug investigation 20050101 |
| Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. | Journal of the International AIDS Society 20050101 |
| Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy. | Journal of the International AIDS Society 20050101 |
| Genetic barriers to resistance and impact on clinical response. | Journal of the International AIDS Society 20050101 |
| A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. | The Journal of biological chemistry 20041231 |
| Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? | Neurology 20041228 |
| Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225 |
| Optimization of unique, uncharged thioesters as inhibitors of HIV replication. | Bioorganic & medicinal chemistry 20041215 |
| Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). | Journal of acquired immune deficiency syndromes (1999) 20041215 |
| A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20041215 |
| C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. | AIDS (London, England) 20041203 |
| Antiretrovirals as antimalarial agents. | The Journal of infectious diseases 20041201 |
| Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20041201 |
| Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. | The Journal of endocrinology 20041201 |
| Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. | Journal of molecular modeling 20041201 |
| Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats. | Die Pharmazie 20041201 |
| Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. | Antiviral therapy 20041201 |
| Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. | Antiviral therapy 20041201 |
| Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy. | Journal of chemotherapy (Florence, Italy) 20041201 |
| Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial. | Clinical therapeutics 20041201 |
| Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. | Chemico-biological interactions 20041120 |
| Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. | AIDS (London, England) 20041119 |
| Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. | Journal of medicinal chemistry 20041118 |
| Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold. | Bioorganic & medicinal chemistry letters 20041115 |
| Residual analysis in linear regression models with an interval-censored covariate. | Statistics in medicine 20041115 |
| CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. | AIDS (London, England) 20041105 |
| Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes. | American journal of physiology. Cell physiology 20041101 |
| Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. | Proteins 20041101 |
| Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101 |
| Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20041101 |
| Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. | Farmaco (Societa chimica italiana : 1989) 20041101 |
| Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. | AIDS research and human retroviruses 20041101 |
| [Therapeutic strategies for HIV infection: clinical approach with boost antiproteases in adults]. | Medecine et maladies infectieuses 20041101 |
| Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015 |
| Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells. | The Journal of infectious diseases 20041015 |
| HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. | Cancer research 20041015 |
| Pseudoaneurysm of the femoral artery in a HIV-infected man. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20041001 |
| The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. | FEMS immunology and medical microbiology 20041001 |
| Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. | Therapeutic drug monitoring 20041001 |
| Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. | Antimicrobial agents and chemotherapy 20041001 |
| Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. | PLoS medicine 20041001 |
| Prevalence of toxoplasma encephalitis in AIDS patients treated with Didanosine hospitalised in a French infectious service. | Current HIV research 20041001 |
| Antiretroviral protease inhibitors prevent l6 muscle cell fusion by reducing calpain activity. | AIDS research and human retroviruses 20041001 |
| Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. | Biochemistry 20040928 |
| Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. | AIDS (London, England) 20040924 |
| P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. | Bioorganic & medicinal chemistry letters 20040920 |
| Indinavir increases glucose production in healthy HIV-negative men. | AIDS (London, England) 20040903 |
| Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20040901 |
| The ICH guidance in practice: stress degradation studies on indinavir sulphate and development of a validated specific stability-indicating HPTLC assay method. | Farmaco (Societa chimica italiana : 1989) 20040901 |
| In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator. | Journal of cellular biochemistry 20040815 |
| HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815 |
| Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. | Journal of virological methods 20040801 |
| Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. | The Journal of antimicrobial chemotherapy 20040801 |
| Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. | Infection 20040801 |
| Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040801 |
| Resistance to HIV protease inhibitors: mechanisms and clinical consequences. | Current drug metabolism 20040801 |
| Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. | American journal of obstetrics and gynecology 20040801 |
| ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. | Antiviral therapy 20040801 |
| [Drug-induced lithiasis]. | Revue medicale de la Suisse romande 20040801 |
| Nail, hair and skin hyperpigmentation associated with indinavir therapy. | AIDS (London, England) 20040723 |
| The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. | The Journal of clinical investigation 20040715 |
| Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040715 |
| Reversed-phase liquid chromatography with ultraviolet detection for simultaneous quantitation of indinavir and propranolol from ex-vivo rat intestinal permeability studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040705 |
| HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). | The Journal of pharmacology and experimental therapeutics 20040701 |
| Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20040701 |
| Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. | HIV medicine 20040701 |
| Thrombosis and a hypercoagulable state in HIV-infected patients. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20040701 |
| Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). | Current medical research and opinion 20040701 |
| Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. | Current medical research and opinion 20040701 |
| Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. | The Journal of biological chemistry 20040625 |
| High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615 |
| Antiviral drugs in current clinical use. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601 |
| Direct interference of HIV protease inhibitors with pancreatic beta-cell function. | Naunyn-Schmiedeberg's archives of pharmacology 20040601 |
| The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. | Antiviral therapy 20040601 |
| Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. | Antiviral therapy 20040601 |
| Pharmacokinetic interactions of drugs with St John's wort. | Journal of psychopharmacology (Oxford, England) 20040601 |
| [Highly Active AntiRetroviral Therapy and cryptosporidiosis]. | Parassitologia 20040601 |
| HIV protease inhibitors increase adiponectin levels in HIV-negative men. | Journal of acquired immune deficiency syndromes (1999) 20040501 |
| Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. | Medical science monitor : international medical journal of experimental and clinical research 20040501 |
| Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. | Pharmaceutical research 20040501 |
| Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection. | AIDS (London, England) 20040409 |
| Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. | Antiviral research 20040401 |
| Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. | European journal of biochemistry 20040401 |
| HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. | Molecular cancer therapeutics 20040401 |
| Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. | Journal of acquired immune deficiency syndromes (1999) 20040401 |
| Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). | Antiviral therapy 20040401 |
| Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing. | Prescrire international 20040401 |
| Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. | Emerging infectious diseases 20040401 |
| Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. | Current HIV/AIDS reports 20040401 |
| Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions. | Life sciences 20040319 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | The Journal of infectious diseases 20040315 |
| Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. | The Journal of infectious diseases 20040315 |
| Protease inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN. | Kidney international 20040301 |
| Anticonvulsant and antiretroviral interactions. | The Annals of pharmacotherapy 20040301 |
| Indinavir and rifabutin drug interactions in healthy volunteers. | Journal of clinical pharmacology 20040301 |
| Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301 |
| Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. | Chinese medical journal 20040301 |
| Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. | International journal of clinical pharmacology and therapeutics 20040301 |
| Spectrophotometric determination of indinavir in bulk and pharmaceutical formulations using bromocresol purple and bromothymol blue. | Die Pharmazie 20040301 |
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20040301 |
| Buffalo hump: what the experts suggest. | AIDS clinical care 20040301 |
| Simultaneous determination of indinavir, ritonavir and saquinavir in plasma by high-performance liquid chromatography. | Journal of the Formosan Medical Association = Taiwan yi zhi 20040301 |
| Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir. | International journal of antimicrobial agents 20040301 |
| Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. | Antiviral research 20040301 |
| Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. | Bioorganic & medicinal chemistry letters 20040223 |
| Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. | AIDS (London, England) 20040220 |
| The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. | International journal of cancer 20040210 |
| Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. | Organic & biomolecular chemistry 20040207 |
| Capillary electrophoretic method for determination of protease inhibitor indinavir sulfate used in human immunodeficiency virus therapy. | Journal of pharmaceutical and biomedical analysis 20040204 |
| Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. | Endocrinology 20040201 |
| Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. | Brain : a journal of neurology 20040201 |
| Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040201 |
| Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. | Analytical chemistry 20040201 |
| [Indinavir urolithiasis in HIV-positive patients. Treatment and prophylaxis]. | Der Urologe. Ausg. A 20040201 |
| Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. | Antiviral therapy 20040201 |
| Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. | Antiviral therapy 20040201 |
| Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. | Antiviral therapy 20040201 |
| Herbal modulation of P-glycoprotein. | Drug metabolism reviews 20040201 |
| IDV concentrations plummet with rifampicin. | IAPAC monthly 20040201 |
| Relapsing blepharitis in patients under highly active antiretroviral therapy including indinavir. | AIDS (London, England) 20040123 |
| Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels. | Biochemical pharmacology 20040115 |
| Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. | Bioorganic & medicinal chemistry 20040102 |
| The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID. | Journal of acquired immune deficiency syndromes (1999) 20040101 |
| In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. | Cancer research 20040101 |
| Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). | HIV medicine 20040101 |
| Determinants of long-term highly active antiretroviral treatment efficacy. | HIV medicine 20040101 |
| Drug-induced renal calculi: epidemiology, prevention and management. | Drugs 20040101 |
| A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). | HIV clinical trials 20040101 |
| Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. | Journal of molecular recognition : JMR 20040101 |
| Peptidomimetic inhibitors of HIV protease. | Current topics in medicinal chemistry 20040101 |
| Pharmacokinetics of indinavir in Koreans and Caucasians. | Scandinavian journal of infectious diseases 20040101 |
| Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. | Journal of medical Internet research 20040101 |
| Urologic problems in patients with acquired immunodeficiency syndrome. | TheScientificWorldJournal 20040101 |
| Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. | Clinical pharmacokinetics 20040101 |
| Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. | Cardiovascular toxicology 20040101 |
| Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. | Cardiovascular toxicology 20040101 |
| [Indinavir and renal lithiasis]. | Actas urologicas espanolas 20040101 |
| Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. | Cardiovascular toxicology 20040101 |
| HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. | Cardiovascular toxicology 20040101 |
| Urolithiasis associated with indinavir in a patient with spinal cord injury. | The journal of spinal cord medicine 20040101 |
| Practical guidelines to interpret plasma concentrations of antiretroviral drugs. | Clinical pharmacokinetics 20040101 |
| HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. | Cardiovascular toxicology 20040101 |
| Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3. | Retrovirology 20040101 |
| Pharmacokinetics of antiretrovirals in pregnant women. | Clinical pharmacokinetics 20040101 |
| Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. | Biochemistry 20031230 |
| Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. | Journal of medicinal chemistry 20031218 |
| Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20031215 |
| TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. | AIDS (London, England) 20031205 |
| Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031201 |
| Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. | Journal of acquired immune deficiency syndromes (1999) 20031201 |
| No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. | British journal of clinical pharmacology 20031201 |
| Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. | Pharmacology 20031201 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults. | Therapeutic drug monitoring 20031201 |
| Photophobia in a patient with high indinavir plasma concentrations. | Therapeutic drug monitoring 20031201 |
| Isolated intraparotid Kaposi sarcoma in human immunodeficiency virus type 1 infection. | Mayo Clinic proceedings 20031201 |
| A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. | Antiviral therapy 20031201 |
| Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. | Antiviral therapy 20031201 |
| HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. | The Journal of biological chemistry 20031128 |
| Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. | Biochemistry 20031125 |
| Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. | AIDS (London, England) 20031121 |
| Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir. | Bioorganic & medicinal chemistry letters 20031117 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
| Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups. | European journal of medical research 20031112 |
| PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. | Proceedings of the National Academy of Sciences of the United States of America 20031111 |
| Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. | AIDS (London, England) 20031107 |
| Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. | Bioorganic & medicinal chemistry 20031103 |
| Influence of goldenseal root on the pharmacokinetics of indinavir. | Journal of clinical pharmacology 20031101 |
| The clinical art and science of urine microscopy. | Current opinion in nephrology and hypertension 20031101 |
| Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa. | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| Treating advanced HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study. | International journal of STD & AIDS 20031101 |
| A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure. | AIDS research and human retroviruses 20031101 |
| [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir]. | Medicina clinica 20031025 |
| Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. | AIDS (London, England) 20031017 |
| Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. | AIDS (London, England) 20031017 |
| Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031015 |
| Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. | Biochemical pharmacology 20031015 |
| HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent. | Bioorganic & medicinal chemistry letters 20031006 |
| [Interaction between methadone and antiretrovirals (stavudine, indinavir, ritonavir, nevirapine)]. | Medicina clinica 20031004 |
| Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. | Journal of lipid research 20031001 |
| Changes in indinavir exposure over time: a case study in six HIV-1-infected children. | The Journal of antimicrobial chemotherapy 20031001 |
| Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20031001 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults. | Therapeutic drug monitoring 20031001 |
| Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. | HIV medicine 20031001 |
| Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. | Journal of acquired immune deficiency syndromes (1999) 20031001 |
| Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. | Antiviral therapy 20031001 |
| A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). | Antiviral therapy 20031001 |
| Atazanavir (Reyataz). | Project Inform perspective 20031001 |
| Anti-HIV agents. High-dose vitamin C may affect indinavir users. | TreatmentUpdate 20031001 |
| Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. | AIDS (London, England) 20030905 |
| Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. | AIDS (London, England) 20030905 |
| Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. | The Journal of antimicrobial chemotherapy 20030901 |
| Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. | The Journal of antimicrobial chemotherapy 20030901 |
| Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors. | The Annals of pharmacotherapy 20030901 |
| A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. | The Journal of infectious diseases 20030901 |
| Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. | The Journal of infectious diseases 20030901 |
| In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. | Antimicrobial agents and chemotherapy 20030901 |
| The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration. | European journal of immunology 20030901 |
| Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901 |
| Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20030901 |
| Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. | The Lancet. Oncology 20030901 |
| The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. | The Journal of endocrinology 20030901 |
| The binding of HIV-1 protease inhibitors to human serum proteins. | Biophysical chemistry 20030901 |
| Overdose reports--an underutilized resource. | Pharmacoepidemiology and drug safety 20030901 |
| A five-year evaluation of reports of overdose with indinavir sulfate. | Pharmacoepidemiology and drug safety 20030901 |
| Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service. | Pharmacotherapy 20030901 |
| Efficacy and durability of nevirapine in antiretroviral drug näive patients. | Journal of acquired immune deficiency syndromes (1999) 20030901 |
| Protein binding in antiretroviral therapies. | AIDS research and human retroviruses 20030901 |
| Boosted PIs: competition hots up. | The AIDS reader 20030901 |
| Characterizing classes of antiretroviral drugs by genotype. | Statistics in medicine 20030830 |
| Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. | Annals of internal medicine 20030819 |
| Summaries for patients. Does marijuana affect viral loads in people with HIV? | Annals of internal medicine 20030819 |
| Virological rebound after suppression on highly active antiretroviral therapy. | AIDS (London, England) 20030815 |
| The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent. | Bioorganic & medicinal chemistry letters 20030804 |
| The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20030804 |
| Push/pull mechanisms of GLUT4 traffic in muscle cells. | Acta physiologica Scandinavica 20030801 |
| HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. | Journal of acquired immune deficiency syndromes (1999) 20030801 |
| Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. | Journal of acquired immune deficiency syndromes (1999) 20030801 |
| Rapid assessment of P-glycoprotein inhibition and induction in vitro. | Pharmaceutical research 20030801 |
| HIV protease inhibitors as new treatment options for Kaposi's sarcoma. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20030801 |
| Vasodilator agents protect against indinavir nephrotoxicity. | Antiviral therapy 20030801 |
| Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. | Antiviral therapy 20030801 |
| Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis. | AIDS (London, England) 20030725 |
| Joint models for efficient estimation in proportional hazards regression models. | Statistics in medicine 20030715 |
| Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. | International journal for parasitology 20030701 |
| HIV protease inhibitors acutely impair glucose-stimulated insulin release. | Diabetes 20030701 |
| Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up. | HIV medicine 20030701 |
| Coadministration of milk thistle and indinavir in healthy subjects. | Pharmacotherapy 20030701 |
| Rapid enzymatic test for phenotypic HIV protease drug resistance. | Biological chemistry 20030701 |
| Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire. | AIDS (London, England) 20030701 |
| Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. | AIDS (London, England) 20030701 |
| Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. | AIDS (London, England) 20030701 |
| Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. | AIDS (London, England) 20030701 |
| Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. | The Journal of infectious diseases 20030615 |
| Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. | Journal of immunology (Baltimore, Md. : 1950) 20030615 |
| A review of low-dose ritonavir in protease inhibitor combination therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030615 |
| Latrogenic nephrogenic diabetes insipidus. | AIDS (London, England) 20030613 |
| Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. | Therapeutic drug monitoring 20030601 |
| Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. | Therapeutic drug monitoring 20030601 |
| Cholelithiasis possibly induced by protease inhibitors in 3 patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601 |
| Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. | Journal of acquired immune deficiency syndromes (1999) 20030601 |
| Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. | The American journal of the medical sciences 20030601 |
| Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. | Xenobiotica; the fate of foreign compounds in biological systems 20030601 |
| Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. | AIDS research and human retroviruses 20030601 |
| Nucleoside-free regimen tested. | AIDS patient care and STDs 20030601 |
| Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. | Antiviral therapy 20030601 |
| Comparison of nine resistance interpretation systems for HIV-1 genotyping. | Antiviral therapy 20030601 |
| Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy. | European journal of medical research 20030530 |
| Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525 |
| Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. | AIDS (London, England) 20030523 |
| Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. | AIDS (London, England) 20030523 |
| Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. | AIDS (London, England) 20030523 |
| Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus. | Bioorganic & medicinal chemistry letters 20030519 |
| [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. | Deutsche medizinische Wochenschrift (1946) 20030509 |
| Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. | Journal of medicinal chemistry 20030508 |
| A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. | AIDS (London, England) 20030502 |
| High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors. | AIDS (London, England) 20030502 |
| Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. | The Journal of antimicrobial chemotherapy 20030501 |
| APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. | The Journal of antimicrobial chemotherapy 20030501 |
| Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. | Diabetologia 20030501 |
| Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. | Chemotherapy 20030501 |
| Once-a-day highly active antiretroviral therapy: a systematic review. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030501 |
| Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. | Antiviral research 20030501 |
| Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. | Seminars in liver disease 20030501 |
| Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. | AIDS patient care and STDs 20030501 |
| [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy]. | Anales de medicina interna (Madrid, Spain : 1984) 20030501 |
| In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH. | The Journal of pharmacy and pharmacology 20030501 |
| [Managing side effects. Individualized dosage makes indinavir more tolerable]. | MMW Fortschritte der Medizin 20030428 |
| Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425 |
| Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains. | Journal of medicinal chemistry 20030424 |
| Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. | Neurology 20030422 |
| Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20030415 |
| Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. | AIDS (London, England) 20030411 |
| Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. | Antimicrobial agents and chemotherapy 20030401 |
| Sildenafil does not alter nelfinavir pharmacokinetics. | Therapeutic drug monitoring 20030401 |
| Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. | The Journal of infectious diseases 20030401 |
| [Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV]. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20030401 |
| Diffuse ulcerations due to disseminated histoplasmosis in a patient with HIV. | Journal of drugs in dermatology : JDD 20030401 |
| HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. | AIDS (London, England) 20030307 |
| Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. | Clinical pharmacology and therapeutics 20030301 |
| Indinavir-induced thrombocytopenia. | AIDS patient care and STDs 20030301 |
| Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. | European journal of medical research 20030221 |
| Measurement of strain-dependent toxicity in the indene bioconversion using multiparameter flow cytometry. | Biotechnology and bioengineering 20030220 |
| Inference for a linear regression model with an interval-censored covariate. | Statistics in medicine 20030215 |
| Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 20030201 |
| The etiology of urolithiasis in HIV infected patients. | The Journal of urology 20030201 |
| Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. | The Annals of pharmacotherapy 20030201 |
| Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. | Journal of acquired immune deficiency syndromes (1999) 20030201 |
| Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. | Biological & pharmaceutical bulletin 20030201 |
| Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Journal of mass spectrometry : JMS 20030201 |
| Synthesis and anti-HIV activity of new C2 symmetric derivatives designed as HIV-1 protease inhibitors. | Farmaco (Societa chimica italiana : 1989) 20030201 |
| The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030201 |
| Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma. | Journal of chromatographic science 20030201 |
| Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy. | International journal of STD & AIDS 20030201 |
| [Antiretrovirals]. | Nihon rinsho. Japanese journal of clinical medicine 20030201 |
| Anti-retroviral protease inhibitors--'a two edged sword?'. | IUBMB life 20030201 |
| Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20030201 |
| [HIV protease inhibitors for the treatment of Kaposi's sarcoma]. | Recenti progressi in medicina 20030201 |
| A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. | Biochemistry 20030128 |
| Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors. | European journal of medical research 20030128 |
| Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. | AIDS (London, England) 20030124 |
| [Fatty liver and increased serum lactate in a woman with HIV]. | Deutsche medizinische Wochenschrift (1946) 20030117 |
| Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115 |
| Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. | AIDS (London, England) 20030103 |
| Drug-induced nail abnormalities. | American journal of clinical dermatology 20030101 |
| Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. | The Journal of pharmacology and experimental therapeutics 20030101 |
| Predicting HIV drug resistance with neural networks. | Bioinformatics (Oxford, England) 20030101 |
| The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. | Journal of lipid research 20030101 |
| 'Multi-component reactions : emerging chemistry in drug discovery' 'from xylocain to crixivan'. | Current medicinal chemistry 20030101 |
| Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir. | HIV clinical trials 20030101 |
| Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. | HIV clinical trials 20030101 |
| In vitro activity of potential anti-poxvirus agents. | Antiviral research 20030101 |
| Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. | Acta dermato-venereologica 20030101 |
| Methadone maintenance treatment and St. John's Wort - a case report. | Pharmacopsychiatry 20030101 |
| Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? | Drugs 20030101 |
| Lopinavir/ritonavir: a review of its use in the management of HIV infection. | Drugs 20030101 |
| [Study of interactions between anti-retroviral agents and concomitant drugs]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101 |
| Lamivudine/zidovudine/abacavir: triple combination tablet. | Drugs 20030101 |
| Saquinavir: a review of its use in boosted regimens for treating HIV infection. | Drugs 20030101 |
| An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination. | HIV clinical trials 20030101 |
| Pharmacokinetic interactions with rifampicin : clinical relevance. | Clinical pharmacokinetics 20030101 |
| Analysis of the pH-dependencies of the association and dissociation kinetics of HIV-1 protease inhibitors. | Journal of molecular recognition : JMR 20030101 |
| Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. | Pharmacoepidemiology and drug safety 20030101 |
| Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. | HIV clinical trials 20030101 |
| Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. | Digestion 20030101 |
| Dietary effects on drug metabolism and transport. | Clinical pharmacokinetics 20030101 |
| [Decrease of HIV-1 replicative capacity after serial passage in MT-4 cells under conditions of the combined antiretroviral therapy]. | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20030101 |
| The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells. | In vitro cellular & developmental biology. Animal 20030101 |
| Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. | The Cochrane database of systematic reviews 20030101 |
| Differences in durability of treatment with initial PI-based regimens. | HIV clinical trials 20030101 |
| Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients, by Ghosn et al. | AIDS (London, England) 20030101 |
| Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. | Drug metabolism and pharmacokinetics 20030101 |
| Drug-induced urinary calculi. | Reviews in urology 20030101 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drinking lots of water still necessary with new indinavir regimens. | TreatmentUpdate 20030101 |
| Onychodystrophy and its management. | German medical science : GMS e-journal 20030101 |
| Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. | Journal of acquired immune deficiency syndromes (1999) 20021215 |
| Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. | Journal of molecular biology 20021206 |
| Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. | AIDS (London, England) 20021206 |
| Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. | Journal of medicinal chemistry 20021205 |
| Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. | Journal of medical virology 20021201 |
| Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. | Archives of internal medicine 20021201 |
| Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. | International journal of antimicrobial agents 20021201 |
| Post-exposure prophylaxis. | International journal of STD & AIDS 20021201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021201 |
| Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. | AIDS (London, England) 20021122 |
| Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study. | The Journal of infectious diseases 20021115 |
| Underpowered clinical trials of antiretroviral treatment. | JAMA 20021106 |
| Application of multi-parameter flow cytometry using fluorescent probes to study substrate toxicity in the indene bioconversion. | Biotechnology and bioengineering 20021105 |
| Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. | Antiviral research 20021101 |
| New anti-HIV agents and targets. | Medicinal research reviews 20021101 |
| Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021101 |
| Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. | Diabetes 20021101 |
| Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O. | Journal of clinical microbiology 20021101 |
| Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boy with AIDS: an unusual clinical presentation. | Journal of pediatric hematology/oncology 20021101 |
| Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. | Pharmaceutical research 20021101 |
| Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data. | Pathologie-biologie 20021101 |
| Population pharmacokinetic meta-analysis with efavirenz. | International journal of clinical pharmacology and therapeutics 20021101 |
| Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'. | Bioorganic & medicinal chemistry letters 20021021 |
| Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. | AIDS (London, England) 20021018 |
| Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis. | AIDS (London, England) 20021018 |
| Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry. | Journal of chromatography. A 20021018 |
| Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. | Journal of pharmaceutical and biomedical analysis 20021015 |
| Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. | Annals of internal medicine 20021015 |
| Hair it is: the long and short of monitoring antiretroviral treatment. | Annals of internal medicine 20021015 |
| Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment. | Annals of internal medicine 20021015 |
| The secreted aspartic proteinases as a new target in the therapy of candidiasis. | Current drug targets 20021001 |
| Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. | Therapeutic drug monitoring 20021001 |
| Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. | Journal of clinical pharmacology 20021001 |
| Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. | Journal of virological methods 20021001 |
| Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. | Pharmacotherapy 20021001 |
| Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery. | The Annals of thoracic surgery 20021001 |
| Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. | HIV medicine 20021001 |
| First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. | HIV medicine 20021001 |
| Indirect hyperbilirubinemia with indinavir. | The Journal of the Association of Physicians of India 20021001 |
| In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome. | Mitochondrion 20021001 |
| [Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir]. | Medicina clinica 20020928 |
| Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. | AIDS (London, England) 20020927 |
| Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. | AIDS (London, England) 20020927 |
| Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. | AIDS research and human retroviruses 20020920 |
| The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). | AIDS (London, England) 20020906 |
| Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20020902 |
| Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains. | Bioorganic & medicinal chemistry letters 20020902 |
| Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901 |
| Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. | The Journal of infectious diseases 20020901 |
| Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. | Diabetes 20020901 |
| The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20020901 |
| The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. | British journal of clinical pharmacology 20020901 |
| Concentrations of protease inhibitors in cord blood after in utero exposure. | The Pediatric infectious disease journal 20020901 |
| Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. | Antiviral therapy 20020901 |
| [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20020901 |
| Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. | AIDS (London, England) 20020816 |
| Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. | AIDS (London, England) 20020816 |
| Generalized hair loss induced by indinavir plus ritonavir therapy. | AIDS (London, England) 20020816 |
| Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020805 |
| Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. | Therapeutic drug monitoring 20020801 |
| Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. | Therapeutic drug monitoring 20020801 |
| Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. | Pediatrics 20020801 |
| Engineering an indene bioconversion process for the production of cis-aminoindanol: a model system for the production of chiral synthons. | Applied microbiology and biotechnology 20020801 |
| Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. | Clinical pharmacology and therapeutics 20020801 |
| Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. | The Pediatric infectious disease journal 20020801 |
| Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection. | European journal of medical research 20020724 |
| New developments in anti-HIV chemotherapy. | Biochimica et biophysica acta 20020718 |
| Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715 |
| Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. | JAMA 20020710 |
| Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. | Biochemistry 20020709 |
| Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds. | Bioorganic & medicinal chemistry letters 20020708 |
| Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. | Archives of internal medicine 20020708 |
| Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. | Proteins 20020701 |
| In vitro antiviral interaction of lopinavir with other protease inhibitors. | Antimicrobial agents and chemotherapy 20020701 |
| Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure. | Journal of medical virology 20020701 |
| Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. | Journal of acquired immune deficiency syndromes (1999) 20020701 |
| Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIV-infected patients during highly- active antiretroviral therapy. | European journal of clinical investigation 20020701 |
| Study of different off-line sample processing procedures and the measurement of antibiotic and antiviral levels in human serum by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020625 |
| Reduced intravertebral bone marrow fat in HIV-infected men. | AIDS (London, England) 20020614 |
| Association between sexual disturbances and sexual hormones with specific antiretroviral drugs. | AIDS (London, England) 20020614 |
| Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. | Biomedical chromatography : BMC 20020601 |
| Self-reported signs of lipodystrophy by persons living with HIV infection. | International journal of STD & AIDS 20020601 |
| High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. | Therapeutic drug monitoring 20020601 |
| Urinary cytology associated with human polyomavirus and indinavir therapy in HIV-infected patients. | American journal of clinical pathology 20020601 |
| Functional expression and localization of P-glycoprotein at the blood brain barrier. | Microscopy research and technique 20020601 |
| Pharmacokinetic interactions between herbal remedies and medicinal drugs. | Xenobiotica; the fate of foreign compounds in biological systems 20020601 |
| Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. | Antiviral therapy 20020601 |
| Select HIV protease inhibitors alter bone and fat metabolism ex vivo. | The Journal of biological chemistry 20020531 |
| A neutravidin-based assay for reverse transcriptase suitable for high throughput screening of retroviral activity. | Journal of biochemistry and molecular biology 20020531 |
| St. John's wort and depression: efficacy, safety and tolerability-an update. | Life sciences 20020517 |
| Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. | The Journal of pharmacology and experimental therapeutics 20020501 |
| Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. | The Annals of pharmacotherapy 20020501 |
| Trizivir. | Expert opinion on pharmacotherapy 20020501 |
| Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. | Pharmacotherapy 20020501 |
| Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. | American journal of hypertension 20020501 |
| Male sexual dysfunction associated with antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| Bone mineral density abnormalities in patients with HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| [St. John's wort (Hypericum perforatum L.). A plant with relevance for dermatology]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20020501 |
| [Ureteral lithiasis caused by Indinavir]. | Revista medica de Chile 20020501 |
| Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. | The Pediatric infectious disease journal 20020501 |
| AIDS-related primary central nervous system lymphoma: prolonged remission associated with highly active antiretroviral therapy. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020501 |
| A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. | Journal of medicinal chemistry 20020425 |
| Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415 |
| Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20020415 |
| Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. | AIDS (London, England) 20020412 |
| HIV protease inhibitors and glucose metabolism. | AIDS (London, England) 20020412 |
| [A plea for an individualized therapy regimen. Which is the optimal dose?]. | MMW Fortschritte der Medizin 20020409 |
| [More transparency facilities drug choice in general practice. Booster regimens in direct comparison]. | MMW Fortschritte der Medizin 20020409 |
| Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401 |
| Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. | Therapeutic drug monitoring 20020401 |
| Indinavir induces acute and reversible peripheral insulin resistance in rats. | Diabetes 20020401 |
| High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. | Journal of acquired immune deficiency syndromes (1999) 20020401 |
| Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. | The Annals of pharmacotherapy 20020401 |
| CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. | Clinical pharmacology and therapeutics 20020401 |
| [Post-exposure prophylaxis in Zambia; the experiences of a tropical disease specialist following a cut accidentally incurred while operating on an HIV positive patient]. | Nederlands tijdschrift voor geneeskunde 20020330 |
| The human 26S proteasome is a target of antiretroviral agents. | AIDS (London, England) 20020329 |
| Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. | AIDS (London, England) 20020329 |
| The utility of inhibitory quotients in determining the relative potency of protease inhibitors. | AIDS (London, England) 20020329 |
| Osteosclerosis and periostal new bone formation during indinavir therapy. | AIDS (London, England) 20020329 |
| Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. | AIDS (London, England) 20020329 |
| The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. | AIDS (London, England) 20020308 |
| Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. | AIDS (London, England) 20020308 |
| Final analysis of the Trilège induction-maintenance trial: results at 18 months. | AIDS (London, England) 20020308 |
| Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. | AIDS (London, England) 20020308 |
| [Mutations of resistance of HIV-1 in previously untreated patients at penitentiary centers of the Autonomous Community of Valencia, Spain. REPRICOVA study]. | Medicina clinica 20020302 |
| [Acute coronary syndromes in patients treated with HIV protease inhibitors]. | Presse medicale (Paris, France : 1983) 20020302 |
| Nelfinavir urinary stones. | The Journal of urology 20020301 |
| Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. | Journal of virology 20020301 |
| HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. | Nature medicine 20020301 |
| Characterizing the relationship between HIV-1 genotype and phenotype: prediction-based classification. | Biometrics 20020301 |
| Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. | Journal of pharmaceutical sciences 20020301 |
| Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand. | The Southeast Asian journal of tropical medicine and public health 20020301 |
| The effects of antiretroviral dose modification on the re-emergence of HIV-1 wild-type strains. | The Southeast Asian journal of tropical medicine and public health 20020301 |
| A combinatorial library of indinavir analogues and its in vitro and in vivo studies. | Bioorganic & medicinal chemistry letters 20020225 |
| A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. | Brain research 20020215 |
| Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. | AIDS (London, England) 20020215 |
| Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen. | AIDS (London, England) 20020215 |
| A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. | Journal of virology 20020201 |
| Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. | Biochimica et biophysica acta 20020201 |
| Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. | Journal of medical virology 20020201 |
| Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. | Protein science : a publication of the Protein Society 20020201 |
| Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). | Journal of clinical psychopharmacology 20020201 |
| Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. | Pediatrics 20020201 |
| In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. | The Journal of pharmacy and pharmacology 20020201 |
| In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. | Planta medica 20020201 |
| Efficacy of highly active antiretroviral therapy in HIV-1 infected children. | The Lancet. Infectious diseases 20020201 |
| [A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection]. | Zhonghua nei ke za zhi 20020201 |
| Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. | AIDS (London, England) 20020125 |
| Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. | AIDS (London, England) 20020125 |
| Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. | AIDS (London, England) 20020125 |
| Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. | AIDS research and human retroviruses 20020120 |
| [Advances in the domain of HIV]. | Presse medicale (Paris, France : 1983) 20020119 |
| Effects of antiretroviral drug combinations on the differentiation of adipocytes. | AIDS (London, England) 20020104 |
| Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. | AIDS (London, England) 20020104 |
| Human infection with Cryptosporidium felis: case report and literature review. | Emerging infectious diseases 20020101 |
| Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. | The Journal of infectious diseases 20020101 |
| Rheumatological complications associated with the use of indinavir and other protease inhibitors. | Annals of the rheumatic diseases 20020101 |
| Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? | Journal of acquired immune deficiency syndromes (1999) 20020101 |
| Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20020101 |
| The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. | The Journal of endocrinology 20020101 |
| Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. | American journal of clinical dermatology 20020101 |
| Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. | HIV clinical trials 20020101 |
| The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. | Clinical pharmacology and therapeutics 20020101 |
| CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. | Xenobiotica; the fate of foreign compounds in biological systems 20020101 |
| St Johns wort increases expression of P-glycoprotein: implications for drug interactions. | British journal of clinical pharmacology 20020101 |
| Epidural lipomatosis secondary to indinavir in an HIV-positive patient. | Clinical neuropharmacology 20020101 |
| Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation. | Acta pharmacologica Sinica 20020101 |
| Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. | Infection 20020101 |
| Interaction between levothyroxine and indinavir in a patient with HIV infection. | Infection 20020101 |
| HIV postexposure prophylaxis in the remote prehospital environment. | Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors 20020101 |
| Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. | Arzneimittel-Forschung 20020101 |
| The role of pharmacokinetics in drug discovery: finding drug candidates with the greatest potential for success. | Ernst Schering Research Foundation workshop 20020101 |
| Retroviral proteases. | Genome biology 20020101 |
| Successful simplification of HAART in patients with acute primary HIV infection. | Journal of biological regulators and homeostatic agents 20020101 |
| Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. | HIV medicine 20020101 |
| A critical evaluation of the therapeutic range of indinavir. | The Annals of pharmacotherapy 20020101 |
| Food-drug interactions. | Drugs 20020101 |
| Evaluation of the origins of the selectivity of polymers imprinted with a HIV protease inhibitor using infrared spectroscopy and high performance liquid chromatography. | Enantiomer 20020101 |
| Clinical implications of CNS penetration of antiretroviral drugs. | CNS drugs 20020101 |
| Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats. | Antiviral chemistry & chemotherapy 20020101 |
| Resistance profiles of cyclic and linear inhibitors of HIV-1 protease. | Antiviral chemistry & chemotherapy 20020101 |
| [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ]. | Therapie 20020101 |
| Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. | The hematology journal : the official journal of the European Haematology Association 20020101 |
| Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. | BMC infectious diseases 20020101 |
| Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma. | BMC cancer 20020101 |
| [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases]. | Annales de dermatologie et de venereologie 20020101 |
| Toxicity. Milk thistle and indinavir. | TreatmentUpdate 20020101 |
| Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. | HIV clinical trials 20020101 |
| Tolerabilities of antiretrovirals in paediatric HIV infection. | Drug safety 20020101 |
| Indinavir-induced retinoid-like effects: incidence, clinical features and management. | Drug safety 20020101 |
| Reversible coma caused by risperidone-ritonavir interaction. | Clinical neuropharmacology 20020101 |
| Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report. | Annals of clinical microbiology and antimicrobials 20020101 |
| [Drug-induced acute pancreatitis: a personal contribution]. | Chirurgia italiana 20020101 |
| Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. | HIV clinical trials 20020101 |
| Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. | International urology and nephrology 20020101 |
| [Acute severe pancreatitis caused by anti-HIV drugs]. | Annali italiani di chirurgia 20020101 |
| [Renal lithiasis due to indinavir]. | Revista de medicina de la Universidad de Navarra 20020101 |
| Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs. | Annali dell'Istituto superiore di sanita 20020101 |
| Antiretroviral therapy 2002: old and new paradigms. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20020101 |
| Management of protease inhibitor-associated hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. | The Journal of biological chemistry 20011221 |
| Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215 |
| Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. | AIDS (London, England) 20011207 |
| Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. | Annals of internal medicine 20011204 |
| Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine. | Annals of internal medicine 20011204 |
| Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20011201 |
| The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes. | International journal of antimicrobial agents 20011201 |
| Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. | British journal of pharmacology 20011201 |
| Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. | Chemistry & biology 20011201 |
| Reduction of signal suppression effects in ESI-MS using a nanosplitting device. | Analytical chemistry 20011201 |
| Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? | European psychiatry : the journal of the Association of European Psychiatrists 20011201 |
| Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection. | Therapeutic drug monitoring 20011201 |
| [Urinary lithiasis secondary to indinavir in an HIV-positive patient]. | Archivos espanoles de urologia 20011201 |
| Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. | Antiviral therapy 20011201 |
| Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations. | Antiviral therapy 20011201 |
| Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). | Antiviral therapy 20011201 |
| [Tuberculosis among HIV-infected persons in Norway]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20011130 |
| Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. | Lancet (London, England) 20011124 |
| Protease inhibitors and erectile dysfunction. | AIDS (London, England) 20011123 |
| HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. | AIDS (London, England) 20011123 |
| The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20011122 |
| Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. | Carbohydrate research 20011121 |
| Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. | AIDS research and human retroviruses 20011120 |
| [Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy]. | Medicina clinica 20011117 |
| Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. | The Journal of infectious diseases 20011115 |
| New developments in anti-HIV chemotherapy. | Current medicinal chemistry 20011101 |
| Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. | The Journal of infectious diseases 20011101 |
| DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. | Antimicrobial agents and chemotherapy 20011101 |
| Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. | Drug and alcohol dependence 20011101 |
| Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. | Metabolism: clinical and experimental 20011101 |
| Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. | Laboratory investigation; a journal of technical methods and pathology 20011101 |
| Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. | The Annals of pharmacotherapy 20011101 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. | Lancet (London, England) 20011020 |
| HIV-protease inhibitors alter retinoic acid synthesis. | AIDS (London, England) 20011019 |
| Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents. | Journal of medicinal chemistry 20011011 |
| Functional expression of P-glycoprotein in rat brain microglia. | The Journal of pharmacology and experimental therapeutics 20011001 |
| Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001 |
| [Skin manifestations of immune restoration syndrome in treated tuberculosis]. | Annales de dermatologie et de venereologie 20011001 |
| Herb-drug interactions: focus on pharmacokinetics. | CNS spectrums 20011001 |
| Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. | Archives of internal medicine 20010910 |
| Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. | The Journal of biological chemistry 20010907 |
| Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. | AIDS (London, England) 20010907 |
| Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. | AIDS (London, England) 20010907 |
| Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | Antiviral research 20010901 |
| Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. | The Journal of antimicrobial chemotherapy 20010901 |
| Incidence and risk factors for the development of indinavir-associated renal complications. | The Journal of antimicrobial chemotherapy 20010901 |
| Application of radiolabeled tracers to biocatalytic flux analysis. | European journal of biochemistry 20010901 |
| Indinavir crystallization around the loop of Henle: experimental evidence. | Journal of acquired immune deficiency syndromes (1999) 20010901 |
| Different combinations of ritonavir-indinavir. | TreatmentUpdate 20010901 |
| Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. | Antiviral therapy 20010901 |
| A case of flare syndrome. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20010901 |
| Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. | AIDS (London, England) 20010817 |
| Antiviral drugs: current state of the art. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801 |
| HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. | Journal of the American Chemical Society 20010801 |
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | Therapeutic drug monitoring 20010801 |
| Papillary necrosis associated with the HIV protease inhibitor indinavir. | Infection 20010801 |
| Antiretroviral rounds. When success is a pain. | AIDS clinical care 20010801 |
| [Paronychia in patients infected with HIV treated with indinavir]. | Revista clinica espanola 20010801 |
| P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? | AIDS (London, England) 20010727 |
| Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. | AIDS (London, England) 20010727 |
| Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. | AIDS (London, England) 20010727 |
| Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. | The Journal of infectious diseases 20010715 |
| The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. | Blood 20010715 |
| High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. | Journal of chromatography. B, Biomedical sciences and applications 20010715 |
| Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy. | Journal of chromatography. A 20010713 |
| Prevalence and predictive value of intermittent viremia with combination hiv therapy. | JAMA 20010711 |
| Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. | AIDS (London, England) 20010706 |
| 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. | Journal of medicinal chemistry 20010705 |
| P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. | The Journal of pharmacology and experimental therapeutics 20010701 |
| CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. | The British journal of ophthalmology 20010701 |
| In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). | British journal of clinical pharmacology 20010701 |
| A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20010701 |
| HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. | FEMS immunology and medical microbiology 20010701 |
| Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. | Human pathology 20010701 |
| Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part I. | The AIDS reader 20010701 |
| Clinical manifestations and management of pediatric HIV infection. | Indian journal of pediatrics 20010701 |
| Indinavir and bones: does thickness = strength? | TreatmentUpdate 20010701 |
| Orofacial effects of antiretroviral therapies. | Oral diseases 20010701 |
| The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. | Archives of biochemistry and biophysics 20010615 |
| Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010615 |
| Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010601 |
| Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | International journal of STD & AIDS 20010601 |
| The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. | Diabetes 20010601 |
| The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. | Diabetes 20010601 |
| [Vertical trasmission of human immunodeficiency virus (HIV) and other sexually transmitted infections (STI)]. | Minerva ginecologica 20010601 |
| Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. | International journal of antimicrobial agents 20010601 |
| The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| Limited sampling approach. | Clinical pharmacology and therapeutics 20010601 |
| The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. | Journal of the American Dietetic Association 20010601 |
| Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. | Antiviral therapy 20010601 |
| Once-a-day indinavir studied. | AIDS patient care and STDs 20010601 |
| Background on glucose--from food to blood sugar. | TreatmentUpdate 20010601 |
| Indinavir--effect on sugar and insulin. | TreatmentUpdate 20010601 |
| Protease inhibitors and blood sugar problems. | TreatmentUpdate 20010601 |
| Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance. | Prescrire international 20010601 |
| Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. | AIDS (London, England) 20010525 |
| Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. | AIDS (London, England) 20010525 |
| 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. | AIDS (London, England) 20010525 |
| Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. | AIDS (London, England) 20010525 |
| Is indinavir crystalluria an indicator for indinavir stone formation? | AIDS (London, England) 20010525 |
| Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. | The Journal of infectious diseases 20010515 |
| [St. John's wort: a pharmaceutical with potentially dangerous interactions]. | Praxis 20010510 |
| Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010505 |
| [Effective in HIV: dual combination with indinavir and ritonavir]. | Deutsche medizinische Wochenschrift (1946) 20010504 |
| Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. | AIDS (London, England) 20010504 |
| Metabolic effects of indinavir in healthy HIV-seronegative men. | AIDS (London, England) 20010504 |
| An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. | Journal of pharmaceutical and biomedical analysis 20010501 |
| Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. | The Journal of infectious diseases 20010501 |
| P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010501 |
| Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. | Endocrinology 20010501 |
| Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. | European journal of biochemistry 20010501 |
| Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization. | AIDS research and human retroviruses 20010501 |
| Efavirenz-induced acute eosinophilic hepatitis. | Journal of hepatology 20010501 |
| [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV]. | Presse medicale (Paris, France : 1983) 20010421 |
| Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415 |
| A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. | Analytical biochemistry 20010415 |
| Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | Journal of chromatography. A 20010413 |
| Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. | AIDS (London, England) 20010413 |
| Indinavir and systemic hypertension. | AIDS (London, England) 20010413 |
| [Didanosine as a capsule. A reliable drug in a new dosage form]. | MMW Fortschritte der Medizin 20010402 |
| Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. | The Journal of infectious diseases 20010401 |
| Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. | The Journal of antimicrobial chemotherapy 20010401 |
| Gynecomastia associated with highly active antiretroviral therapy. | The Annals of pharmacotherapy 20010401 |
| Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. | Journal of clinical pharmacology 20010401 |
| Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1. | Molecular therapy : the journal of the American Society of Gene Therapy 20010401 |
| Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. | AIDS patient care and STDs 20010401 |
| CT appearances of HIV-related lipodystrophy syndrome. | The British journal of radiology 20010401 |
| Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. | The Journal of infection 20010401 |
| Principles and practice of HIV-protease inhibitor pharmacoenhancement. | HIV medicine 20010401 |
| Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. | AIDS (London, England) 20010330 |
| Competition prompts drug companies to cut antiretroviral drug prices. | Lancet (London, England) 20010317 |
| Anti-AIDS drugs available 'at cost'. | Nature 20010315 |
| Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. | AIDS (London, England) 20010309 |
| Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. | JAMA 20010307 |
| Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. | The Journal of infectious diseases 20010301 |
| Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy. | The Journal of infectious diseases 20010301 |
| Resolution of microsporidial keratoconjunctivitis in an AIDS patient treated with highly active antiretroviral therapy. | American journal of ophthalmology 20010301 |
| A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. | Journal of acquired immune deficiency syndromes (1999) 20010301 |
| The safety and antiviral effect of protease inhibitors in children. | Pharmacotherapy 20010301 |
| Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients. | The Journal of pharmacy and pharmacology 20010301 |
| HIV/AIDS case histories: indinavir crystalluria. | AIDS patient care and STDs 20010301 |
| Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20010301 |
| A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. | International journal of clinical pharmacology and therapeutics 20010301 |
| Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. | Antiviral therapy 20010301 |
| Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. | Lancet (London, England) 20010224 |
| [Anti-infection prophylaxis after sexual assault. Experience of the Raymond Poincaré-Garches Hospital]. | Presse medicale (Paris, France : 1983) 20010217 |
| Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. | The Journal of infectious diseases 20010201 |
| Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. | Drug metabolism and disposition: the biological fate of chemicals 20010201 |
| Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. | International journal of antimicrobial agents 20010201 |
| Association between high serum prolactin levels and concomitant infections in HIV-infected patients. | Human immunology 20010201 |
| Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20010201 |
| Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study. | International journal of STD & AIDS 20010201 |
| [Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]. | Annales de medecine interne 20010201 |
| [Acute porphyria and indinavir]. | Annales de dermatologie et de venereologie 20010201 |
| Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20010201 |
| [Resistance to protease inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20010201 |
| The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. | AIDS (London, England) 20010126 |
| Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. | AIDS research and human retroviruses 20010120 |
| Indinavir, zidovudine, lamivudine: 3-year follow-up. | Annals of internal medicine 20010116 |
| Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2. | AIDS (London, England) 20010105 |
| Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. | AIDS (London, England) 20010105 |
| Paronychia in association with indinavir treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010101 |
| Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. | Antimicrobial agents and chemotherapy 20010101 |
| Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. | British journal of clinical pharmacology 20010101 |
| Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20010101 |
| The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir. | International journal of STD & AIDS 20010101 |
| The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. | Drugs 20010101 |
| Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. | PharmacoEconomics 20010101 |
| [Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20010101 |
| [Simultaneous quantitative determination of amprenavir and indinavir in human plasma by high-performance liquid chromatography]. | Annales de biologie clinique 20010101 |
| Delavirdine: clinical pharmacokinetics and drug interactions. | Clinical pharmacokinetics 20010101 |
| Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. | Scandinavian journal of infectious diseases 20010101 |
| Saquinavir soft gelatin capsule: a comparative safety review. | Drug safety 20010101 |
| New developments in anti-HIV chemotherapy. | Farmaco (Societa chimica italiana : 1989) 20010101 |
| Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies. | BMC medical research methodology 20010101 |
| Clinically significant drug interactions with agents specific for migraine attacks. | CNS drugs 20010101 |
| [Drug interactions with antiretroviral agents]. | Therapie 20010101 |
| Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. | The Annals of pharmacotherapy 20010101 |
| Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy. | The Annals of pharmacotherapy 20010101 |
| Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases. | Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101 |
| Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor. | Journal of biological regulators and homeostatic agents 20010101 |
| [AIDS, activism, and the regulation of clinical trials in Brazil: Protocol 028]. | Cadernos de saude publica 20010101 |
| Development of HIV protease inhibitors: a survey. | Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20010101 |
| A peptide inhibitor of HIV-1 protease using alpha, beta- dehydro residues: a structure based computer model. | Indian journal of biochemistry & biophysics 20010101 |
| Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients. | European cytokine network 20010101 |
| Ritonavir and indinavir one year later. | TreatmentUpdate 20010101 |
| Using ritonavir with indinavir in cases of virologic failure. | TreatmentUpdate 20010101 |
| Merck pushes the envelope with once-daily indinavir. | TreatmentUpdate 20010101 |
| Human immunodeficiency virus-hepatitis C coinfection: swapping new problems for newer ones. | Internal medicine journal 20010101 |
| Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals. | HIV clinical trials 20010101 |
| The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. | HIV clinical trials 20010101 |
| Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. | HIV clinical trials 20010101 |
| Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. | Clinical laboratory 20010101 |
| Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. | HIV clinical trials 20010101 |
| The use of efavirenz as a part of late rescue antiretroviral treatment. | HIV clinical trials 20010101 |
| Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. | HIV medicine 20010101 |
| Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. | BMC microbiology 20010101 |
| Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients. | HIV clinical trials 20010101 |
| Unenhanced spiral CT in acute ureteral colic: a replacement for excretory urography? | Korean journal of radiology 20010101 |
| Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. | Journal of molecular graphics & modelling 20010101 |
| Interactions between herbal medicines and prescribed drugs: a systematic review. | Drugs 20010101 |
| Sugar blues and protease inhibitors. | TreatmentUpdate 20010101 |
| 'In vitro' antifungal activity of protease inhibitors. | Mycopathologia 20010101 |
| [Nephropathy caused by crystal deposits induced by indinavir]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101 |
| [Nephrolithiasis in a HIV infected patient treated with indinavir]. | Przeglad lekarski 20010101 |
| Metabolic engineering of indene bioconversion in Rhodococcus sp. | Advances in biochemical engineering/biotechnology 20010101 |
| In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. | Journal of human virology 20010101 |
| The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). | Psychopharmacology bulletin 20010101 |
| A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. | Psychopharmacology bulletin 20010101 |
| 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. | Journal of medicinal chemistry 20001228 |
| Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20001215 |
| Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. | The Journal of urology 20001201 |
| Symptomatic crystalluria associated with indinavir. | The Annals of pharmacotherapy 20001201 |
| PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. | Antimicrobial agents and chemotherapy 20001101 |
| Leucocytoclastic vasculitis and indinavir. | The British journal of dermatology 20001101 |
| Sudden anuria due to indinavir crystalluria. | Nephron 20001101 |
| Inhibition of HIV-1 protease by a boron-modified polypeptide. | Biochemical pharmacology 20001001 |
| Pyuria in patients treated with indinavir is associated with renal dysfunction. | Clinical nephrology 20001001 |
| [Anuria in HIV+ patients treated with indinavir]. | Archivos espanoles de urologia 20001001 |
| Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. | Journal of medicinal chemistry 20000921 |
| Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. | AIDS (London, England) 20000908 |
| Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. | Journal of medicinal chemistry 20000907 |
| In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. | Antimicrobial agents and chemotherapy 20000901 |
| Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. | Antimicrobial agents and chemotherapy 20000901 |
| Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report. | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20000901 |
| BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. | Antimicrobial agents and chemotherapy 20000801 |
| Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. | Journal of virology 20000801 |
| Glutathione oxidation and PTPase inhibition by hydrogen peroxide in Caco-2 cell monolayer. | American journal of physiology. Gastrointestinal and liver physiology 20000801 |
| 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. | Annals of internal medicine 20000704 |
| Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. | Antiviral chemistry & chemotherapy 20000701 |
| Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds. | Bioorganic & medicinal chemistry letters 20000605 |
| Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. | Biochemical pharmacology 20000501 |
| A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. | Journal of virology 20000501 |
| Indinavir calculi: diagnosis with magnetic resonance urography. | European urology 20000501 |
| In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. | The Journal of infectious diseases 20000501 |
| Urinary cytology changes in protease inhibitor induced urolithiasis. | The Journal of urology 20000401 |
| Acute tubulointerstitial nephritis attributable to indinavir therapy. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20000401 |
| 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease. | Journal of medicinal chemistry 20000309 |
| Severe hypertension and renal atrophy associated with indinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20000301 |
| Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. | Antiviral chemistry & chemotherapy 20000301 |
| Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. | Antiviral therapy 20000301 |
| Protease inhibitors: current status and future prospects. | Journal of medicinal chemistry 20000210 |
| A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. | AIDS (London, England) 20000128 |
| In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. | AIDS (London, England) 20000107 |
| Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. | The American journal of medicine 19991201 |
| [Hemolytic anemia associated with indinavir administration]. | Enfermedades infecciosas y microbiologia clinica 19991101 |
| Treatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable by rehydration. | BJU international 19991001 |
| Failure of indinavir to inhibit Candida albicans in vitro. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19991001 |
| Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. | Journal of medicinal chemistry 19990923 |
| Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. | The Journal of biological chemistry 19990820 |
| In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. | The Journal of infectious diseases 19990801 |
| Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990801 |
| Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. | The Journal of urology 19990601 |
| [Treatment of complicated renal colic in patients treated with indinavir: value of double J stents]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 19990601 |
| Urolithiasis associated with protease inhibitors. | Journal of endourology 19990501 |
| Acute renal failure caused by indinavir in a patient with a single functioning kidney. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19990501 |
| Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990501 |
| Haemolytic anaemia associated with indinavir. | Postgraduate medical journal 19990501 |
| Images in clinical medicine. Indinavir crystalluria. | The New England journal of medicine 19990429 |
| Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. | The Journal of urology 19990401 |
| Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. | AIDS (London, England) 19990311 |
| Indinavir-induced nephropathy. | Clinical nephrology 19990301 |
| [Indinavir-induced anuria]. | Revista clinica espanola 19990301 |
| Case no. 3. Right flank pain. Crixivan lithiasis. | Techniques in urology 19990301 |
| [Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients]. | Presse medicale (Paris, France : 1983) 19990227 |
| Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. | Antimicrobial agents and chemotherapy 19990201 |
| Persistent flank pain, low-grade fever, and malaise in a woman treated with indinavir. | AIDS patient care and STDs 19990201 |
| [Hydronephrosis caused by indinavir]. | Enfermedades infecciosas y microbiologia clinica 19990101 |
| Urolithiasis and the protease inhibitor indinavir. | European urology 19990101 |
| Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis. | The American journal of medicine 19990101 |
| Changes in renal function associated with indinavir. | AIDS (London, England) 19981224 |
| Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. | AIDS (London, England) 19981224 |
| Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. | AIDS (London, England) 19981224 |
| Persistent nephrolithiasis after discontinuation of indinavir therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19981201 |
| [Clinical case of the month. Apropos of pancytopenia in a seropositive patient]. | Revue medicale de Liege 19981201 |
| Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. | Biochemistry 19981027 |
| Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. | Virology 19981025 |
| Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. | AIDS (London, England) 19981022 |
| Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. | Antimicrobial agents and chemotherapy 19981001 |
| Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19981001 |
| Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. | Chemistry & biology 19981001 |
| Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. | Journal of medicinal chemistry 19980924 |
| Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. | AJR. American journal of roentgenology 19980901 |
| Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. | Clinical nephrology 19980901 |
| New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. | Journal of medicinal chemistry 19980827 |
| Crystalluria and urinary tract abnormalities associated with indinavir. | The Journal of urology 19980801 |
| Ureteral obstruction secondary to indinavir in the pediatric HIV population. | Pediatric radiology 19980801 |
| Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. | The New England journal of medicine 19980730 |
| Nephrolithiasis from indinavir, a new human immunodeficiency virus drug. | The Journal of urology 19980601 |
| S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 19980601 |
| Subtle occurrence of indinavir-induced acute renal insufficiency. | AIDS (London, England) 19980528 |
| Selected highlights on women and HIV from the 5th Conference on Retroviruses and Opportunistic Infections. | BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 19980401 |
| [Nephritic colic due to indinavir]. | Presse medicale (Paris, France : 1983) 19980314 |
| Indinavir-induced renal failure. | AIDS (London, England) 19980305 |
| Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. | Archives of pathology & laboratory medicine 19980301 |
| [Hepatic steatosis during treatment with zidovudine and lamivudine in an HIV-positive patient]. | Nederlands tijdschrift voor geneeskunde 19980221 |
| Indinavir and interstitial nephritis. | Annals of internal medicine 19980215 |
| Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis. | The Journal of urology 19980201 |
| Indinavir-associated hepatitis in patients with advanced HIV infection. | International journal of STD & AIDS 19980101 |
| In vitro selection and characterization of VX-478 resistant HIV-1 variants. | Advances in experimental medicine and biology 19980101 |
| Acute interstitial nephritis secondary to the administration of indinavir. | The Annals of pharmacotherapy 19980101 |
| The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. | Pharmaceutical biotechnology 19980101 |
| Nonsymmetrically substituted cyclic urea HIV protease inhibitors. | Journal of medicinal chemistry 19971205 |
| [Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate]. | Presse medicale (Paris, France : 1983) 19971108 |
| Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor. | AIDS (London, England) 19971101 |
| Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. | Antiviral research 19971101 |
| [Hemolytic jaundice related to ingestion of indinavir]. | Presse medicale (Paris, France : 1983) 19971101 |
| Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. | Biochemistry 19971007 |
| Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. | American journal of kidney diseases : the official journal of the National Kidney Foundation 19971001 |
| Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. | The Annals of pharmacotherapy 19971001 |
| Protease inhibitor-induced urolithiasis. | Urology 19971001 |
| Urolithiasis associated with the protease inhibitor indinavir. | Urology 19971001 |
| Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. | Journal of virology 19970901 |
| An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. | Journal of medicinal chemistry 19970801 |
| Crystalluria and urinary tract abnormalities associated with indinavir. | Annals of internal medicine 19970715 |
| Protease inhibitors and urolithiasis. | The Journal of urology 19970701 |
| Indinavir-induced nephropathy. | Tennessee medicine : journal of the Tennessee Medical Association 19970701 |
| [Crystalluria and nephrolithiasis during therapy with the protease inhibitor indinavir]. | Deutsche medizinische Wochenschrift (1946) 19970613 |
| Urinary stones in HIV-1-positive patients treated with indinavir. | Lancet (London, England) 19970503 |
| In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. | The Journal of infectious diseases 19970501 |
| Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. | Antimicrobial agents and chemotherapy 19970501 |
| [Kidney colic under Indinavir [correction of indiavir] therapy in HIV infection]. | Praxis 19970430 |
| Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. | Biochimica et biophysica acta 19970425 |
| A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. | Antimicrobial agents and chemotherapy 19970301 |
| Indinavir nephrolithiasis in warm climates. | Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 19970301 |
| Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. | Drug metabolism and disposition: the biological fate of chemicals 19970201 |
| Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. | Journal of medicinal chemistry 19970117 |
| Indinavir nephropathy. | The New England journal of medicine 19970109 |
| Indinavir urinary stones as origin of upper urinary tract obstruction. | Urologia internationalis 19970101 |
| [A new cause of nephritic colic: indinavir. Apropos of a case]. | La Revue de medecine interne 19970101 |
| [Urinary calculi and indinavir sulfate in patients with HIV infection. Apropos of 4 cases]. | Journal d'urologie 19970101 |
| Medical alert: hemolytic anemia in Crixivan cohort. | Critical Path AIDS project 19970101 |
| Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. | The Journal of biological chemistry 19961213 |
| Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. | Journal of virology 19961201 |
| HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. | Journal of medicinal chemistry 19961011 |
| Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. | Antimicrobial agents and chemotherapy 19960601 |
| Protease inhibitors shine in triple combinations. | AIDS alert 19960301 |
| Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 19960220 |
| In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. | Antiviral research 19960101 |
| Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. | AIDS research and human retroviruses 19960101 |
| In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. | Journal of virology 19950901 |
| Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. | Biochemistry 19950725 |
| In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. | Nature 19950406 |
| L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. | Journal of medicinal chemistry 19941014 |
| Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. | Journal of medicinal chemistry 19940610 |
| L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. | Proceedings of the National Academy of Sciences of the United States of America 19940426 |
| Educating the learning disabled adolescent about sexuality. | Journal of learning disabilities 19791101 |